<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.1 20151215//EN" "https://jats.nlm.nih.gov/publishing/1.1/JATS-journalpublishing1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" specific-use="sps-1.9" dtd-version="1.1" xml:lang="pt" article-type="research-article">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher-id">abc</journal-id>
      <journal-title-group>
        <journal-title>Arquivos Brasileiros de Cardiologia</journal-title>
        <abbrev-journal-title abbrev-type="publisher">Arq. Bras. Cardiol.</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0066-782X</issn>
      <issn pub-type="epub">1678-4170</issn>
      <publisher>
        <publisher-name>Sociedade Brasileira de Cardiologia - SBC</publisher-name>
        <publisher-loc>S&#227;o Paulo, SP, Brazil</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v3">NGqKDkCjRYCbZJyhyM3977M</article-id>
      <article-id pub-id-type="other">00001</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v2">S0066-782X2010001500001</article-id>
      <article-id pub-id-type="publisher-id" specific-use="scielo-v1">S0066-782X(10)09500501</article-id>
      <article-id pub-id-type="doi">10.1590/S0066-782X2010005000139</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Artigos Originais</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Avalia&#231;&#227;o n&#227;o invasiva de pacientes submetidos &#224; interven&#231;&#227;o percut&#226;nea no infarto do mioc&#225;rdio</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Buchler</surname>
            <given-names>Rica Dodo Delmar</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ribeiro</surname>
            <given-names>Expedito E.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mansur</surname>
            <given-names>Antonio de Padua</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Smanio</surname>
            <given-names>Paola</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Meneghelo</surname>
            <given-names>Romeu Sergio</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chalela</surname>
            <given-names>William Azem</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Buchpiguel</surname>
            <given-names>Carlos Alberto</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Buchler</surname>
            <given-names>Jorge Roberto</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Bates</surname>
            <given-names>Eric R.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Martinez</surname>
            <given-names>Eulogio E.</given-names>
          </name>
          <xref ref-type="aff" rid="aff01"/>
        </contrib>
      </contrib-group>
      <aff id="aff01">
        <addr-line>
          <named-content content-type="city">AnnArbor</named-content>
          <named-content content-type="state">Michigan</named-content>
        </addr-line>
        <institution content-type="orgname">Universidade de S&#227;o Paulo</institution>
        <institution content-type="orgdiv1">Faculdade de Medicina </institution>
        <institution content-type="orgdiv2">Instituto do Cora&#231;&#227;o</institution>
      </aff>
      <pub-date date-type="collection" publication-format="electronic">
        <month>10</month>
        <year>2010</year>
      </pub-date>
      <volume>95</volume>
      <issue>5</issue>
      <fpage>555</fpage>
      <lpage>562</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>05</month>
          <year>2009</year>
        </date>
        <date date-type="accepted">
          <day>13</day>
          <month>05</month>
          <year>2010</year>
        </date>
        <date date-type="rev-recd">
          <day>04</day>
          <month>04</month>
          <year>2010</year>
        </date>
      </history>
      <permissions>
        <license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/" xml:lang="en">
          <license-p>This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>FUNDAMENTO: A reestenose p&#243;s-interven&#231;&#227;o coronariana percut&#226;nea prim&#225;ria permanece um problema de relev&#226;ncia cl&#237;nica, mesmo com o implante de stents. A capacidade das provas n&#227;o invasivas para detec&#231;&#227;o de reestenose n&#227;o foi totalmente demonstrada. OBJETIVO: Avaliar a habilidade do teste ergom&#233;trico (TE) e da cintilografia de perfus&#227;o mioc&#225;rdica (CPM) no diagn&#243;stico de reestenose em pacientes com infarto agudo do mioc&#225;rdio, e supradenivelamento do segmento ST, submetidos &#224; angioplastia coronariana percut&#226;nea prim&#225;ria (ACPP), com implante de stent nas primeiras 12 horas de evolu&#231;&#227;o. M&#201;TODOS: De Ago/2003-Jan/2006, foram selecionados 64 pacientes (ps) (56,2 &#177; 10,2 anos, 53 homens) submetidos &#224; ACPP. Apenas ps com fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo &gt; 40,0%, definida por ecocardiograma de repouso, foram inclu&#237;dos. Teste ergom&#233;trico, com as 12 deriva&#231;&#245;es do ECG associadas a precordiais direitas, e CPM foram realizados 6 semanas, 6 meses e um ano ap&#243;s o tratamento. Foi realizada cinecoronariografia no 6&#186; m&#234;s. RESULTADOS: Doen&#231;a uniarterial ocorreu em 46,9% dos ps, sendo a art&#233;ria descendente anterior tratada em 48,4%. Reestenose angiogr&#225;fica ocorreu em 28,8%. Sensibilidade, especificidade, valor preditivo positivo (VPP), valor preditivo negativo (VPN) e acur&#225;cia do TE para detec&#231;&#227;o de reestenose n&#227;o foram significativos. A adi&#231;&#227;o de deriva&#231;&#245;es precordiais direitas n&#227;o proporcionou informa&#231;&#245;es adicionais. Sensibilidade, especificidade, VPP, VPN e acur&#225;cia da CPM apresentaram correla&#231;&#227;o com reestenose apenas no 6&#186; m&#234;s, considerando-se summed difference score &gt; 2 (p = 0,006) e &gt; 4 (p = 0,014). CONCLUS&#195;O: O TE n&#227;o discriminou reestenose. A CPM realizada no 6&#186; m&#234;s foi relacionada &#224; reestenose e mostrou-se &#250;til durante a evolu&#231;&#227;o.</p>
      </abstract>
      <kwd-group xml:lang="pt" kwd-group-type="author-generated">
        <kwd>Reestenose coron&#225;ria</kwd>
        <kwd>angioplastia</kwd>
        <kwd>stent</kwd>
        <kwd>infarto do mioc&#225;rdio</kwd>
        <kwd>procedimentos cl&#237;nicos</kwd>
      </kwd-group>
      <pub-date publication-format="electronic" date-type="pub">
        <day>22</day>
        <month>10</month>
        <year>2010</year>
      </pub-date>
    </article-meta>
  </front>
  <body>
    <p>
      <bold>Avalia&#231;&#227;o n&#227;o invasiva de pacientes submetidos &#224; interven&#231;&#227;o percut&#226;nea no infarto do mioc&#225;rdio</bold>
    </p>
    <p>
      <bold>Rica Dodo Delmar Buchler; Expedito E. Ribeiro; Antonio de Padua Mansur; Paola Smanio; Romeu Sergio Meneghelo; William Azem Chalela; Carlos Alberto Buchpiguel; Jorge Roberto Buchler; Eric R. Bates; Eulogio E. Martinez</bold>
    </p>
    <p> Instituto do Cora&#231;&#227;o (InCor) da Faculdade de Medicina da Universidade de S&#227;o Paulo, Instituto Dante Pazzanese de Cardiologia, University Of Michigan - AnnArbor - Michigan</p>
    <p>
      <xref ref-type="corresp" rid="nt">Correspond&#234;ncia</xref>
    </p>
    <p>
      <bold>RESUMO</bold>
    </p>
    <p><bold>FUNDAMENTO:</bold> A reestenose p&#243;s-interven&#231;&#227;o coronariana percut&#226;nea prim&#225;ria permanece um problema de relev&#226;ncia cl&#237;nica, mesmo com o implante de <italic>stents</italic>. A capacidade das provas n&#227;o invasivas para detec&#231;&#227;o de reestenose n&#227;o foi totalmente demonstrada. </p>
    <p><bold>OBJETIVO:</bold> Avaliar a habilidade do teste ergom&#233;trico (TE) e da cintilografia de perfus&#227;o mioc&#225;rdica (CPM) no diagn&#243;stico de reestenose em pacientes com infarto agudo do mioc&#225;rdio, e supradenivelamento do segmento ST, submetidos &#224; angioplastia coronariana percut&#226;nea prim&#225;ria (ACPP), com implante de <italic>stent</italic> nas primeiras 12 horas de evolu&#231;&#227;o. </p>
    <p><bold>M&#201;TODOS:</bold> De Ago/2003-Jan/2006, foram selecionados 64 pacientes (ps) (56,2 &#177; 10,2 anos, 53 homens) submetidos &#224; ACPP. Apenas ps com fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo <underline>&gt;</underline> 40,0%, definida por ecocardiograma de repouso, foram inclu&#237;dos. Teste ergom&#233;trico, com as 12 deriva&#231;&#245;es do ECG associadas a precordiais direitas, e CPM foram realizados 6 semanas, 6 meses e um ano ap&#243;s o tratamento. Foi realizada cinecoronariografia no 6&#186; m&#234;s. </p>
    <p><bold>RESULTADOS:</bold> Doen&#231;a uniarterial ocorreu em 46,9% dos ps, sendo a art&#233;ria descendente anterior tratada em 48,4%. Reestenose angiogr&#225;fica ocorreu em 28,8%. Sensibilidade, especificidade, valor preditivo positivo (VPP), valor preditivo negativo (VPN) e acur&#225;cia do TE para detec&#231;&#227;o de reestenose n&#227;o foram significativos. A adi&#231;&#227;o de deriva&#231;&#245;es precordiais direitas n&#227;o proporcionou informa&#231;&#245;es adicionais. Sensibilidade, especificidade, VPP, VPN e acur&#225;cia da CPM apresentaram correla&#231;&#227;o com reestenose apenas no 6&#186; m&#234;s, considerando-se <italic>summed difference score</italic> &gt; 2 (p = 0,006) e &gt; 4 (p = 0,014). </p>
    <p><bold>CONCLUS&#195;O:</bold> O TE n&#227;o discriminou reestenose. A CPM realizada no 6&#186; m&#234;s foi relacionada &#224; reestenose e mostrou-se &#250;til durante a evolu&#231;&#227;o. </p>
    <p><bold>Palavras-chave:</bold> Reestenose coron&#225;ria, angioplastia, <italic>stent</italic>, infarto do mioc&#225;rdio, procedimentos cl&#237;nicos.</p>
    <p>
      <bold>Introdu&#231;&#227;o</bold>
    </p>
    <p>A angioplastia coronariana percut&#226;nea prim&#225;ria (ACCP) &#233; superior ao tratamento fibrinol&#237;tico no tratamento do infarto agudo do mioc&#225;rdio com supradesnivelamento do segmento ST<sup>1</sup>. Devido aos elevados &#237;ndices de reestenose, os <italic>stents</italic> coron&#225;rios surgiram como nova estrat&#233;gia, por&#233;m a reestenose permanece como fator limitante, com &#237;ndices entre 20,0%-25,0%<sup>2,3</sup>, quando utilizados <italic>stents</italic> sem elui&#231;&#227;o de medicamentos.</p>
    <p>A realiza&#231;&#227;o apropriada de provas n&#227;o invasivas ap&#243;s ACPP n&#227;o foi sistematicamente investigada. Dentre as provas n&#227;o invasivas, o teste ergom&#233;trico (TE) e a cintilografia de perfus&#227;o mioc&#225;rdica (CPM) t&#234;m sido utilizados para a identifica&#231;&#227;o de reestenose. O TE &#233; seguro, simples e facilmente realizado. A adi&#231;&#227;o de deriva&#231;&#245;es precordiais direitas tem sido adotada para melhorar a sensibilidade do TE<sup>4</sup>. Por outro lado, a sensibilidade da CPM para identifica&#231;&#227;o de reestenose pode variar entre 39,0%-100,0% e 46,0%-100,0%, respectivamente, e aumenta com o tempo decorrido ap&#243;s a revasculariza&#231;&#227;o<sup>5</sup>.</p>
    <p>O objetivo deste estudo foi determinar o valor progn&#243;stico do TE e da CPM na detec&#231;&#227;o de reestenose <italic>intrastent</italic> durante o seguimento cl&#237;nico ap&#243;s ACPP.</p>
    <p>
      <bold>Material e m&#233;todos</bold>
    </p>
    <p>A angioplastia prim&#225;ria com implante de <italic>stent</italic> durante a fase aguda do infarto do mioc&#225;rdio foi conduzida em dois centros por operadores experientes. Os pacientes realizaram TE e CPM com 6 semanas, depois com 6 meses e, por &#250;ltimo, um ano ap&#243;s a interven&#231;&#227;o. Os TE foram realizados em vig&#234;ncia da medica&#231;&#227;o prescrita, inclusive com betabloqueadores. Cineangiocoronariografia foi realizada durante o 6&#186; m&#234;s de evolu&#231;&#227;o. O ecocardiograma transtor&#225;cico com o paciente em repouso foi realizado previamente &#224; alta hospitalar, com a finalidade de avaliar a fra&#231;&#227;o de eje&#231;&#227;o do ventr&#237;culo esquerdo (FEVE) para inclus&#227;o do paciente no protocolo.</p>
    <p>O estudo foi aprovado pelos Comit&#234;s de &#201;tica de ambas as Institui&#231;&#245;es e todos os pacientes assinaram termo de consentimento livre e esclarecido. O estudo foi conduzido de acordo com os princ&#237;pios cl&#237;nicos da declara&#231;&#227;o de Helsinki para investiga&#231;&#245;es em humanos.</p>
    <p>
      <bold>Popula&#231;&#227;o ou casu&#237;stica</bold>
    </p>
    <p>Durante o per&#237;odo compreendido entre ago/2003-jan/2006, em acompanhamento prospectivo, foram selecionados 80 pacientes com infarto agudo do mioc&#225;rdio com supradesnivelamento do segmento ST tratados por angioplastia coronariana prim&#225;ria com implante de <italic>stent</italic> durante as primeiras 12 horas de evolu&#231;&#227;o, no Instituto do Cora&#231;&#227;o da FMUSP-InCor e no Instituto Dante Pazzanese de Cardiologia em S&#227;o Paulo. Os crit&#233;rios de inclus&#227;o foram: idade <underline>&lt;</underline> 75 anos, aus&#234;ncia de infarto pr&#233;vio, classe Killip 1<sup>6</sup>, FEVE <underline>&gt;</underline> 40,0% avaliado por ecocardiograma transtor&#225;cico em repouso e capacidade para realizar teste ergom&#233;trico em esteira.</p>
    <p><italic>Stents</italic> sem elui&#231;&#227;o de medicamentos foram utilizados em todos os pacientes. Dezesseis pacientes (20,0%) foram exclu&#237;dos: 5 por n&#227;o preencherem os crit&#233;rios ecocardiogr&#225;ficos de elegibilidade, 11 por n&#227;o completarem o protocolo de estudo at&#233; o final. Sendo assim, 64 pacientes foram acompanhados por pelo menos um ano.</p>
    <p>Todas as interven&#231;&#245;es foram realizadas de acordo com as diretrizes atuais, inclusive com inibidores da glicoprote&#237;na IIb/IIIa a crit&#233;rio do operador<sup>7</sup>. Os crit&#233;rios de sucesso angiogr&#225;fico foram estenose residual do vaso tratado <underline>&lt;</underline> 30,0% e presen&#231;a de fluxo TIMI 3<sup>8</sup>. Foi tratado apenas o vaso relacionado ao infarto.</p>
    <p>
      <bold>Protocolo do estudo ou m&#233;todos</bold>
    </p>
    <p>
      <bold>Ecocardiogramas</bold>
    </p>
    <p>Os exames doppler ecocardiogr&#225;ficos foram realizados previamente &#224; alta hospitalar com equipamento Ultramark -9 HDI da marca ATL (<italic>Advanced Technology Laboratories Inc</italic>., Cherry Hills, NJ). O m&#233;todo de Simpson foi utilizado para obten&#231;&#227;o da FEVE<sup>9</sup>. Este exame definiu a inclus&#227;o e a posterior perman&#234;ncia do paciente no protocolo de estudo.</p>
    <p>
      <bold>Testes ergom&#233;tricos</bold>
    </p>
    <p>Todos os pacientes realizaram TE sintoma limitante, de acordo com o protocolo de Bruce<sup>10</sup>, e cintilografia de perfus&#227;o mioc&#225;rdica com capta&#231;&#227;o tomogr&#225;fica (SPECT) sincronizada ao ECG (Gated&#150;SPECT). A monitoriza&#231;&#227;o foi realizada com as 12 deriva&#231;&#245;es do ECG associadas &#224;s deriva&#231;&#245;es precordiais direitas, V3R, V4R e V5R com a finalidade de aumentar a sensibilidade e a especificidade da prova de esfor&#231;o. O TE foi realizado em concord&#226;ncia com diretrizes previamente descritas<sup>11</sup>. A capacidade funcional foi avaliada pela dura&#231;&#227;o do exerc&#237;cio em minutos e pelo n&#250;mero de METS atingido, aplicando-se a equa&#231;&#227;o descrita por Bruce<sup>12</sup> (um MET = 3,5 ml O<sub>2</sub>/kg/minuto).</p>
    <p>Foi considerado crit&#233;rio eletrocardiogr&#225;fico de isquemia mioc&#225;rdica a presen&#231;a de infradesnivelamento do segmento ST de morfologia ascendente ou horizontal <underline>&gt;</underline> 1 mm, 80 ms ap&#243;s o ponto J em mais de tr&#234;s complexos QRS consecutivos, em presen&#231;a ou n&#227;o de dor precordial. O infradesnivelamento de morfologia descendente foi avaliado em n&#237;vel de ponto J. A angina foi considerada crit&#233;rio cl&#237;nico de isquemia mioc&#225;rdica. O escore de Duke foi calculado, segundo f&#243;rmula previamente descrita<sup>13</sup>.</p>
    <p>No pico do exerc&#237;cio, foram injetados por via endovenosa, em bolus, de 444 a 555 mBQ de sestamibi, marcados com tecn&#233;cio 99-m. Os pacientes continuaram a exercitar-se por um minuto antes da interrup&#231;&#227;o do esfor&#231;o. Antes da fase de esfor&#231;o, a mesma dose de sestamibi foi injetada em repouso. A cintilografia foi realizada de acordo com a t&#233;cnica de <italic>Gated SPECT</italic>, entre 60 e 90 minutos ap&#243;s a inje&#231;&#227;o do radiof&#225;rmaco.</p>
    <p>
      <bold>Cintilografia de perfus&#227;o mioc&#225;rdica - protocolo de aquisi&#231;&#227;o das imagens</bold>
    </p>
    <p>As aquisi&#231;&#245;es foram realizadas segundo a metodologia descrita previamente<sup>14</sup>. O <italic>SPECT(Single Photon Emission Computed Tomography)</italic> foi realizado com gama c&#226;mara rotat&#243;ria (CardioMD, Philips Medical Systems, Milpitas, CA, USA) e as imagens foram adquiridas com matriz 64 x 64 e janela de 20,0% com fotopico em 140 keV foi utilizada.</p>
    <p>A perfus&#227;o mioc&#225;rdica foi avaliada por an&#225;lise qualitativa e semiquantitativa. Para a an&#225;lise qualitativa, a perfus&#227;o foi classificada em normal, isquemia transit&#243;ria (hipocapta&#231;&#227;o apenas no esfor&#231;o), fibrose ou hipoperfus&#227;o fixa (hipocapta&#231;&#227;o em ambas as fases) e hipoperfus&#227;o fixa e transit&#243;ria (coexist&#234;ncia de tecido isqu&#234;mico e fibr&#243;tico, hipocapta&#231;&#227;o durante a fase de estresse e com melhora parcial durante a fase de repouso).</p>
    <p>Dois observadores independentes e experientes avaliaram as imagens. Para a an&#225;lise semiquantitativa, o ventr&#237;culo esquerdo foi dividido em 17 segmentos e os defeitos de perfus&#227;o foram analisados com a utiliza&#231;&#227;o do sistema de escores de zero a 4: 0 - capta&#231;&#227;o normal; 1 - redu&#231;&#227;o discreta da perfus&#227;o; 2 - diminui&#231;&#227;o moderada da perfus&#227;o; 3 - redu&#231;&#227;o acentuada da perfus&#227;o mioc&#225;rdica; e 4 - aus&#234;ncia de capta&#231;&#227;o do marcador.</p>
    <p>O <italic>Summed Stress Score</italic> foi obtido com o somat&#243;rio dos escores atribu&#237;dos a cada segmento derivado das imagens obtidas ao esfor&#231;o (estresse f&#237;sico). O <italic>Summed Rest Score </italic>foi obtido pelo somat&#243;rio dos escores atribu&#237;dos a cada segmento derivado das imagens obtidas em repouso. O <italic>Summed Difference Score, </italic>que representa a magnitude da isquemia mioc&#225;rdica, foi definido como a diferen&#231;a entre os escores de estresse e repouso<sup>15 </sup>e foi considerado defeito revers&#237;vel quando foi &gt; 2.</p>
    <p>A an&#225;lise de todos os segmentos permitiu identificar &#225;reas de isquemia relacionadas a vasos n&#227;o tratados.</p>
    <p>
      <bold>Reestudo angiogr&#225;fico</bold>
    </p>
    <p>Todos os estudos foram realizados utilizando-se a t&#233;cnica de Judkins, 6 meses ap&#243;s a ACPP, com cateteres 5 ou 6 French. Reestenose <italic>intrastent</italic> foi definida como les&#227;o quando foi <underline>&gt;</underline> 50,0%, avaliada por angiografia coron&#225;ria quantitativa.</p>
    <p>
      <bold>Desfechos </bold>
    </p>
    <p>&#211;bito, infarto do mioc&#225;rdio ou revasculariza&#231;&#227;o do vaso tratado foram considerados eventos maiores. Infarto agudo do mioc&#225;rdio foi definido segundo crit&#233;rios previamente descritos<sup>16</sup>. Considerou-se revasculariza&#231;&#227;o do vaso alvo a repeti&#231;&#227;o do tratamento (percut&#226;neo ou cir&#250;rgico) decorrente de les&#227;o localizada no vaso tratado.</p>
    <p>
      <bold>An&#225;lise estat&#237;stica</bold>
    </p>
    <p>As vari&#225;veis cont&#237;nuas foram expressas em m&#233;dia e desvio-padr&#227;o e foram comparadas utilizando-se o teste <italic>t Student</italic>. As vari&#225;veis categ&#243;ricas foram descritas atrav&#233;s de frequ&#234;ncias absolutas e relativas. &#205;ndices de sensibilidade, especificidade, valor preditivo positivo, valor preditivo negativo e acur&#225;cia foram calculados para TE e CPM considerando-se os resultados do reestudo angiogr&#225;fico. As associa&#231;&#245;es entre vari&#225;veis categ&#243;ricas foram verificadas atrav&#233;s dos testes qui-quadrado ou teste exato de Fischer. O teste <italic>t Student</italic> ou o teste n&#227;o param&#233;trico de Mann-Whitney foram utilizados para vari&#225;veis cont&#237;nuas que n&#227;o apresentaram normalidade. O n&#237;vel de signific&#226;ncia foi estabelecido em 0,05. A concord&#226;ncia interobservadores para interpreta&#231;&#227;o das CPM foi avaliada pela medida estat&#237;stica Kappa.</p>
    <p>
      <bold>Resultados</bold>
    </p>
    <p>As caracter&#237;sticas cl&#237;nicas dos pacientes encontram-se na <xref ref-type="table" rid="tab1">Tabela 1</xref>. O tempo m&#233;dio de dor, desde o inicio dos sintomas at&#233; o atendimento, foi de 4 horas, e o tempo porta-bal&#227;o foi de 75 minutos.</p>
    <table-wrap id="tab1">
      <graphic xlink:href="1678-4170-abc-95-05-0555-00139-gt01.jpg"/></table-wrap>
    <p>
      <bold>Cinecoronariografia</bold>
    </p>
    <p>A art&#233;ria descendente anterior foi tratada em 31 ps (48,4%), a coron&#225;ria direita em 22 (34,4%), a circunflexa em 7 (10,9%), o tronco de coron&#225;ria esquerda em duas (3,1%), o grande ramo diagonal em uma (1,56%) e a ponte safena em uma (1,56%). Doen&#231;a multiarterial (outras les&#245;es coron&#225;rias <underline>&gt;</underline> 50,0%) foi observada em 34 pacientes (53,1%). Revasculariza&#231;&#227;o completa foi realizada com sucesso em 30 ps com les&#227;o uniarterial e, em tr&#234;s pacientes, multiarteriais previamente revascularizados. O di&#226;metro de refer&#234;ncia m&#233;dia do vaso pr&#233; e p&#243;s-procedimento foi de 2,9 &#177; 0,5 mm e 3,2 &#177; 0,4 mm, respectivamente. O di&#226;metro luminal m&#237;nimo pr&#233; e p&#243;s-procedimento foi respectivamente de 0,34 &#177; 0,4 mm e 2,81 &#177; 0,4 mm.</p>
    <p>O grau de estenose pr&#233; e p&#243;s-procedimento foi de 87,7% &#177; 14,6% e 7,5% &#177; 4,2%, respectivamente.</p>
    <p>O reestudo angiogr&#225;fico foi realizado em 59/64 pacientes, tr&#234;s antes de 6 meses (um deles, durante o terceiro m&#234;s de evolu&#231;&#227;o, devido a angina e dois, durante o 4&#186; m&#234;s, devido a s&#237;ndrome coron&#225;ria aguda). Reestenose angiogr&#225;fica ocorreu em 17 pacientes (28,8%), 8 com estenose de 50,0%-70,0% e 9 com estenose <underline>&gt;</underline> 70,0%. Uma nova revasculariza&#231;&#227;o do vaso alvo ocorreu em 18,6% dos casos. O di&#226;metro de refer&#234;ncia final foi de 2,63 &#177; 0,72 mm e o di&#226;metro luminal m&#237;nimo foi de 1,95 &#177; 0,90 mm. A estenose final m&#233;dia foi 39 &#177; 25,0%. N&#227;o houve diferen&#231;a quanto &#224; reestenose em pacientes com doen&#231;a uni ou multiarterial.</p>
    <p>
      <bold>Ecocardiogramas</bold>
    </p>
    <p>A FEVE m&#233;dia observada ao exame realizado para inclus&#227;o do paciente no protocolo foi de 0,55.</p>
    <p>
      <bold>Testes ergom&#233;tricos</bold>
    </p>
    <p>Os exames foram realizados em vig&#234;ncia da terap&#234;utica prescrita ap&#243;s a alta hospitalar. O uso de betabloqueadores esteve presente em 85,0%, 79,0% e 66,7% dos casos, durante os TE realizados 6 semanas, 6 meses e 12 meses, respectivamente. Clopidogrel ou ticlopidina foram prescritos em 45,9%, 7,5% e 7,5%, respectivamente. Os dados dos testes ergom&#233;tricos seriados encontram-se na <xref ref-type="table" rid="tab2">Tabela 2</xref>.</p>
    <table-wrap id="tab2">
      <graphic xlink:href="1678-4170-abc-95-05-0555-00139-gt02.jpg"/></table-wrap>
    <p>Os valores de sensibilidade, especificidade, VPP, VPN e acur&#225;cia dos TE, quando comparados aos achados no reestudo angiogr&#225;fico, podem ser observados na <xref ref-type="table" rid="tab3">Tabela 3</xref>. Quando considerados os pacientes que atingiram 85,0% da frequ&#234;ncia card&#237;aca m&#225;xima prevista, os &#237;ndices de sensibilidade, especificidade, valor preditivo positivo e valor preditivo negativo e acur&#225;cia para detec&#231;&#227;o de reestenose foram 63,6%, 67,7%, 41,2%, 84,0% e 66,7%, respectivamente, com 6 semanas (p = 0,086); 55,6%, 83,3%, 55,6%, 83,3% e 75,7%, aos 6 meses (p = 0,073); e 40,0%, 66,7%, 30,8%, 75,0% e 59,4%, aos 12 meses ap&#243;s o tratamento do infarto (p = 0,716).</p>
    <table-wrap id="tab3">
      <graphic xlink:href="1678-4170-abc-95-05-0555-00139-gt03.jpg"/></table-wrap>
    <p>N&#227;o houve correla&#231;&#227;o entre reestenose e escore de Duke, tempo de exerc&#237;cio, angina ao esfor&#231;o, depress&#227;o do segmento ST ou altera&#231;&#245;es em deriva&#231;&#245;es precordiais direitas. Foi observado maior tempo de exerc&#237;cio entre o primeiro e o segundo TE (p = 0,004) e entre o primeiro e o terceiro TE (p = 0,004) nos 46 ps que realizaram as tr&#234;s provas consecutivas. O mesmo foi observado em rela&#231;&#227;o aos METS atingidos (p = 0,002 e p = 0,004, respectivamente).</p>
    <p>
      <bold>Cintilografia mioc&#225;rdica</bold>
    </p>
    <p>Os resultados da an&#225;lise qualitativa podem ser observados na <xref ref-type="table" rid="tab4">Tabela 4</xref>.</p>
    <table-wrap id="tab4">
      <graphic xlink:href="1678-4170-abc-95-05-0555-00139-gt04.jpg"/></table-wrap>
    <p>A an&#225;lise semiquantitativa considerou isquemia transit&#243;ria o <italic>Summed Difference Score</italic> &gt; 2, e para a mesma casu&#237;stica foi tamb&#233;m avaliado o escore &gt; 4; os dados resultantes dessa an&#225;lise est&#227;o na <xref ref-type="table" rid="tab5">Tabela 5</xref>. A an&#225;lise interobservadores foi significativamente concordante, com medida Kappa = 0,762 ( 95% IC, 0,51- 1,0) p &lt; 0,001<sup>17</sup>.</p>
    <table-wrap id="tab5">
      <graphic xlink:href="1678-4170-abc-95-05-0555-00139-gt05.jpg"/></table-wrap>
    <p>O <italic>Summed Difference Score</italic> durante o primeiro ano, em 46 pacientes que realizaram todas as CPM sequenciais, n&#227;o evidenciou &#237;ndices estatisticamente significativos (p = 0,194). A compara&#231;&#227;o entre os <italic>Summed Difference Score</italic> observados 6 semanas, 6 meses e um ano ap&#243;s a ACPP e a reestenose n&#227;o atingiu signific&#226;ncia (p = 0,056). Os <italic>Summed Stress Scores</italic> e os <italic>Summed Rest Scores</italic> foram comparados com reestenose em todas as CPM e foram subdivididos em 0 a 4, 4 a 8 e &gt;8, de acordo com a extens&#227;o do mioc&#225;rdio acometido. Houve correla&#231;&#227;o entre a extens&#227;o de mioc&#225;rdio afetado e reestenose no exame de um ano, em repouso (p = 0,0019) e ap&#243;s estresse f&#237;sico (p = 0,004).</p>
    <p>
      <bold>Evolu&#231;&#227;o</bold>
    </p>
    <p>Reestenose angiogr&#225;fica ocorreu em 17/59 pacientes (28,8%). Trombose subaguda do <italic>stent</italic> foi observada em um paciente, 27 dias ap&#243;s a ACPP. S&#237;ndrome coron&#225;ria aguda sem supradenivelamento de segmento ST ocorreu em dois pacientes durante o 4&#186; m&#234;s (um deles foi tratado por revasculariza&#231;&#227;o cir&#250;rgica e outro por angioplastia com bal&#227;o). A reestenose foi tratada em 11 pacientes (18,6%). Revasculariza&#231;&#227;o cir&#250;rgica em tr&#234;s (um com reestenose &gt; 50,0% e &lt; 70,0% e angina) e angioplastia em 8 (dois com reestenose &gt; 50,0% e &lt; 70,0% e angina). Em 6 pacientes com reestenose, n&#227;o foi realizado nenhum procedimento. Em 7 pacientes, foi realizada angioplastia em art&#233;rias n&#227;o relacionadas ao infarto. N&#227;o ocorreram &#243;bitos durante o <italic>follow-up</italic>.</p>
    <p>Quarenta e quatro pacientes evolu&#237;ram assintom&#225;ticos durante o primeiro ano, 11 apresentaram dor precordial at&#233; o 6&#186; m&#234;s (7 com reestenose, dos quais 5 com les&#227;o <underline>&gt;</underline> 70,0%) e 9 relataram sintomas ap&#243;s 6 meses de evolu&#231;&#227;o.</p>
    <p>
      <bold>Discuss&#227;o</bold>
    </p>
    <p>Reestenose angiogr&#225;fica ocorreu em 17 pacientes (28,8%). Nos estudos PAMI-PILOT<sup>18</sup>, STENT-PAMI<sup>16 </sup>e CADILLAC<sup>3</sup>, as taxas foram 27,0%, 23,0% e 22,0%, respectivamente. Como descrito por Cutlip e cols.<sup>19</sup>, acompanhamos os pacientes durante um ano para estimar o &#237;ndice real de sucesso<sup>19</sup>. Nos estudos STENT-PAMI e CADILLAC, o seguimento foi realizado por 6 meses, e, no GRAMI<sup>20</sup> e STENTIM<sup>21</sup>, foi mantido durante um ano.</p>
    <p>A reinterven&#231;&#227;o tardia ap&#243;s ACPP ocorre em 3,6% a 22,7% dos casos<sup>3,16,22</sup>. No presente estudo, a revasculariza&#231;&#227;o do vaso alvo foi de 18,6%. A indica&#231;&#227;o apropriada das provas n&#227;o invasivas para detec&#231;&#227;o de reestenose ap&#243;s ACPP ainda permanece discut&#237;vel. O TE &#233; utilizado rotineiramente para detec&#231;&#227;o de isquemia residual, determina&#231;&#227;o da capacidade funcional e estratifica&#231;&#227;o de risco ap&#243;s infarto agudo do mioc&#225;rdio, al&#233;m de ser o exame mais frequentemente realizado para avaliar pacientes submetidos &#224; interven&#231;&#227;o percut&#226;nea<sup>23-25</sup>.</p>
    <p>&#201; descrito que o exerc&#237;cio agudo pode induzir estado protromb&#243;tico transit&#243;rio em pacientes com doen&#231;a coron&#225;ria<sup>26</sup>. Casos de trombose do <italic>stent</italic>, ocorridos horas ap&#243;s a realiza&#231;&#227;o do TE, foram previamente descritos<sup>27,28</sup>. Em nosso estudo, os TE foram realizados sem complica&#231;&#245;es.</p>
    <p>As diretrizes atuais para realiza&#231;&#227;o de TE ap&#243;s interven&#231;&#245;es percut&#226;neas n&#227;o recomendam a realiza&#231;&#227;o rotineira da prova para detec&#231;&#227;o de reestenose<sup>11</sup>, por&#233;m n&#227;o h&#225; dados suficientes para determinar a correta estrat&#233;gia, especialmente em pacientes com elevado risco de reestenose como em les&#245;es proximais de DA.</p>
    <p>O racional da estrat&#233;gia de indica&#231;&#227;o rotineira de provas funcionais ap&#243;s ICP baseia-se na teoria de que o diagn&#243;stico de isquemia silenciosa permite estratificar os pacientes de pior progn&#243;stico<sup>5</sup>. Estudos previamente realizados demonstraram que o TE apresenta baixa sensibilidade e limitada capacidade para localiza&#231;&#227;o da isquemia<sup>11,29</sup>. A dor precordial n&#227;o representa &#237;ndice confi&#225;vel de desenvolvimento de reestenose ap&#243;s interven&#231;&#245;es percut&#226;neas, uma vez que aproximadamente 50,0% dos pacientes com reestenose permanecem assintom&#225;ticos e, inversamente, at&#233; 45,0% dos pacientes que desenvolvem dor precordial n&#227;o t&#234;m reestenose angiogr&#225;fica<sup>5</sup>. Por esse motivo, n&#227;o realizamos o estudo apenas com pacientes assintom&#225;ticos.</p>
    <p>Em pacientes com revasculariza&#231;&#227;o incompleta, a resposta isqu&#234;mica pode ser consequente &#224; reestenose ou &#224; isquemia mioc&#225;rdica n&#227;o relacionada ao vaso tratado.</p>
    <p>Dados de metan&#225;lise relatam sensibilidade e especificidade do TE, em 46,0% e 77,0%, respectivamente, para les&#227;o reesten&#243;tica &gt; 50,0% e 50,0% e 84,0%, respectivamente, para reestenose &gt; 70%<sup>29</sup>. O TE realizado 6 semanas ap&#243;s o infarto evidenciou baixa sensibilidade e especificidade moderada. Embora o TE para identifica&#231;&#227;o de reestenose seja realizado no 6&#186; m&#234;s, n&#227;o encontramos sensibilidade e especificidade superiores aos obtidos no TE precoce, por&#233;m o elevado valor preditivo negativo ressalta a import&#226;ncia da prova n&#227;o isqu&#234;mica na abordagem cl&#237;nica desses pacientes.</p>
    <p>Foram relatados resultados semelhantes de sensibilidade e especificidade, com menor valor preditivo negativo (61,0%) em pacientes sintom&#225;ticos ap&#243;s interven&#231;&#227;o percutanea<sup>25</sup>. O primeiro estudo comparativo entre a estrat&#233;gia rotineira e seletiva para realiza&#231;&#227;o do TE ap&#243;s interven&#231;&#245;es percut&#226;neas foi o estudo ADORE, que avaliou pacientes submetidos &#224; revasculariza&#231;&#227;o completa sem reestudo angiogr&#225;fico durante a evolu&#231;&#227;o. A realiza&#231;&#227;o rotineira dos TE n&#227;o demonstrou benef&#237;cios sobre a estrat&#233;gia seletiva em que os pacientes realizaram TE desencadeados por sintomas<sup>30</sup>.</p>
    <p>No presente estudo, n&#227;o houve associa&#231;&#227;o com reestenose em presen&#231;a de revasculariza&#231;&#227;o completa ou incompleta, mesmo nos pacientes que ultrapassaram 85,0% da frequ&#234;ncia card&#237;aca m&#225;xima prevista. Nossos dados confirmam a baixa sensibilidade da angina e as altera&#231;&#245;es eletrocardiogr&#225;ficas desencadeadas pelo esfor&#231;o para detec&#231;&#227;o de reestenose<sup>31</sup>.</p>
    <p>N&#227;o observamos melhor sensibilidade do TE com a adi&#231;&#227;o das deriva&#231;&#245;es precordiais direitas, semelhante ao descrito em outros estudos<sup>32,33</sup> e contrariamente aos resultados obtidos por Michaelides e cols.<sup>4</sup>.</p>
    <p>A m&#233;dia de METS obtidos foi de 8, o que pode ser explicado pelos rigorosos crit&#233;rios de inclus&#227;o como fra&#231;&#227;o de eje&#231;&#227;o &gt; 40,0%. Em pacientes ap&#243;s infarto, a capacidade funcional &gt; 4 METS em associa&#231;&#227;o &#224; fra&#231;&#227;o de eje&#231;&#227;o de ventr&#237;culo esquerdo <underline>&gt;</underline> 40,0% apresentou correla&#231;&#227;o com boa evolu&#231;&#227;o<sup>34</sup>. De acordo com o estudo DANAMI-2, pacientes com baixa capacidade funcional ap&#243;s infarto agudo do mioc&#225;rdio apresentam maiores &#237;ndices de mortalidade<sup>35</sup>.</p>
    <p>O TE associado &#224; CPM apresenta melhor desempenho diagn&#243;stico que a prova de esfor&#231;o isolada<sup>25</sup>. A CPM &#233; frequentemente realizada ap&#243;s interven&#231;&#245;es percut&#226;neas para detectar reestenose e identificar outras &#225;reas de isquemia mioc&#225;rdica correspondentes a vasos n&#227;o tratados<sup>36</sup>. Em nosso estudo, a CPM realizada na 6&#170; semana evidenciou baixa sensibilidade que pode ser explicada por les&#245;es intermedi&#225;rias ou por uso de medica&#231;&#245;es. A especificidade e valor preditivo negativo apresentaram valores moderados.</p>
    <p>Devido aos elevados &#237;ndices falso positivos, a cintilografia mioc&#225;rdica precoce, realizada durante os primeiros tr&#234;s meses ap&#243;s interven&#231;&#245;es percut&#226;neas, n&#227;o deve ser rotineiramente indicada<sup>5</sup>. Rodes Cabau e cols.<sup>37</sup> observaram defeitos revers&#237;veis em 17,0% dos pacientes submetidos &#224; CPM uma semana ap&#243;s ACPP, com sensibilidade de 50,0% e especificidade de 54,0%. Todavia esse fato pode n&#227;o excluir a possibilidade de reestenose. Em dois casos de nossa amostra, em que os pacientes apresentaram s&#237;ndrome coron&#225;ria aguda durante o 4&#186; m&#234;s de evolu&#231;&#227;o, n&#227;o foi observada isquemia revers&#237;vel 6 semanas ap&#243;s a ACPP.</p>
    <p>Em nosso estudo, a CPM realizada aos 6 e 12 meses mostrou baixa sensibilidade, por&#233;m elevada especificidade, especialmente no 6&#186; m&#234;s, considerando-se o <italic>summed difference score &gt; </italic>2 e &gt; 4. Dados de sensibilidade, especificidade, valor preditivo positivo e valor preditivo negativo podem ter sofrido influ&#234;ncia da terap&#234;utica vigente. A acur&#225;cia da CPM realizada 6 meses ap&#243;s a interven&#231;&#227;o &#233; geralmente muito boa<sup>5</sup>.</p>
    <p>Galassi e cols.<sup>31</sup> encontraram acur&#225;cia semelhante (83,0%) em pacientes que atingiram ou n&#227;o a frequ&#234;ncia card&#237;aca m&#225;xima durante TE associado &#224; CPM. Os autores conclu&#237;ram que o mais importante &#233; a homogeneidade da popula&#231;&#227;o, semelhante ao presente estudo, quanto ao tipo de estresse e tempo decorrido entre o procedimento percut&#226;neo e a cintilografia e entre a cintilografia e o reestudo angiogr&#225;fico. A inclus&#227;o de territ&#243;rios com infarto pr&#233;vio n&#227;o afetou a acur&#225;cia da CPM. Diferentemente de nosso estudo, os autores avaliaram apenas revasculariza&#231;&#245;es completas. </p>
    <p>Isaaz e cols.<sup>38</sup> relataram, em recente estudo, baixa correla&#231;&#227;o entre cintilografia com SPECT e reestenose angiogr&#225;fica no 6&#186; m&#234;s em 149 pacientes tratados por ACPP, que permanecem assintom&#225;ticos durante o <italic>follow up</italic>. Para a detec&#231;&#227;o de reestenose, a sensibilidade, especificidade, valor preditivo positivo e valor preditivo negativo e acur&#225;cia foram 48,0%, 61,0%, 35,0%, 72,0% e 57,0%, respectivamente<sup>38</sup>. Por dois anos e meio, os autores acompanharam 78 pacientes, apenas os uniarteriais. </p>
    <p>Nossos resultados evidenciaram uma melhor especificidade e um valor preditivo negativo. Kosa e cols.<sup>39</sup> relataram que altera&#231;&#245;es preexistentes da perfus&#227;o mioc&#225;rdica em territ&#243;rios com infarto pr&#233;vio podem acarretar em menores &#237;ndices de sensibilidade e especificidade. Popula&#231;&#245;es heterog&#234;neas podem ser respons&#225;veis por algumas discrep&#226;ncias observadas nos estudos. </p>
    <p>A sensibilidade e a especificidade da com, observada em tempos diferentes ap&#243;s interven&#231;&#245;es percut&#226;neas, variam entre 39,0% a 100,0%, e entre 46,0% a 100,0%, aumentando proporcionalmente ao tempo decorrido ap&#243;s a revasculariza&#231;&#227;o<sup>5</sup>.</p>
    <p>A presen&#231;a de defeitos revers&#237;veis &#224; CPM realizada entre 12 e 18 meses ap&#243;s interven&#231;&#245;es percut&#226;neas est&#225; associada ao maior risco de eventos durante a evolu&#231;&#227;o. A extens&#227;o e a severidade dos defeitos revers&#237;veis da perfus&#227;o ao SPECT possuem elevado valor preditivo para sobrevida tardia ap&#243;s interven&#231;&#245;es percut&#226;neas<sup>15</sup>. Esse dado justificou a realiza&#231;&#227;o da cintilografia um ano ap&#243;s o procedimento em nosso estudo.</p>
    <p>A fra&#231;&#227;o de eje&#231;&#227;o determinada pelo GATED-SPECT quando &lt; 40,0% foi relacionada a mau progn&#243;stico durante o seguimento cl&#237;nico<sup>40</sup>. Em nossa casu&#237;stica, a boa evolu&#231;&#227;o pode ser explicada pela fra&#231;&#227;o de eje&#231;&#227;o &gt; 45,0% observada nas cintilografias evolutivas. Sabemos que pacientes com fra&#231;&#227;o de eje&#231;&#227;o &gt; 40,0% n&#227;o representam a totalidade do mundo real, mas, em centros terci&#225;rios, a ACPP pode ser realizada durante as primeiras horas de evolu&#231;&#227;o do IAM, assim &#233; poss&#237;vel encontrar pacientes com fra&#231;&#227;o de eje&#231;&#227;o preservada e obter dados de provas n&#227;o invasivas, semelhantes aos obtidos ap&#243;s interven&#231;&#245;es eletivas.</p>
    <p>
      <bold>Implica&#231;&#245;es cl&#237;nicas</bold>
    </p>
    <p>O valor preditivo negativo da CPM realizada 6 meses ap&#243;s ACPP &#233; elevado. A aus&#234;ncia de isquemia revers&#237;vel pode ser considerada indicativa de aus&#234;ncia de reestenose (ou da express&#227;o funcional da reestenose) nesta amostra selecionada de pacientes.</p>
    <p>
      <bold>Limita&#231;&#245;es do estudo</bold>
    </p>
    <p>Citamos o pequeno n&#250;mero da amostra, a inclus&#227;o de pacientes que evolu&#237;ram em classe Killip 1, fra&#231;&#227;o de eje&#231;&#227;o <underline>&gt;</underline> 40,0% e a manuten&#231;&#227;o da medica&#231;&#227;o prescrita durante todo o protocolo. A amostra foi pequena devido &#224; coexist&#234;ncia de v&#225;rios protocolos em andamento em ambas as Institui&#231;&#245;es, o que n&#227;o tornava poss&#237;vel a inclus&#227;o do mesmo paciente em v&#225;rios protocolos. </p>
    <p>A escolha de pacientes com fra&#231;&#227;o de eje&#231;&#227;o &gt; 400% foi feita para garantir a realiza&#231;&#227;o dos testes ergom&#233;tricos. A manuten&#231;&#227;o de medica&#231;&#245;es como betabloqueadores pode afetar a resposta da frequ&#234;ncia card&#237;aca ao esfor&#231;o, mas nossa inten&#231;&#227;o foi avaliar a amostra do mundo real dos pacientes ap&#243;s ACPP.</p>
    <p>
      <bold>Conclus&#245;es</bold>
    </p>
    <p>Podemos concluir que o TE evidenciou baixa sensibilidade para detectar reestenose ap&#243;s ACPP durante o seguimento cl&#237;nico. A adi&#231;&#227;o de deriva&#231;&#245;es precordiais n&#227;o proporcionou informa&#231;&#245;es adicionais. A CPM realizada 6 meses ap&#243;s o procedimento apresentou correla&#231;&#227;o com reestenose, evidenciando alta especificidadee VPNnesta popula&#231;&#227;o de pacientes.</p>
    <p>
      <bold>Potencial Conflito de Interesses</bold>
    </p>
    <p> Declaro n&#227;o haver conflito de interesses pertinentes.</p>
    <p>
      <bold>Fontes de Financiamento</bold>
    </p>
    <p> O presente estudo n&#227;o teve fontes de financiamento externas.</p>
    <p>
      <bold>Vincula&#231;&#227;o Acad&#234;mica</bold>
    </p>
    <p> Este artigo &#233; parte de tese de Doutorado de Rica Dodo Delmar Buchler pela Faculdade de Medicina da Universidade de S&#227;o Paulo.</p>
    <p>
      <fn id="nt" fn-type="corresp">
        <label>
          <bold>Correspond&#234;ncia:</bold>
        </label>
        <p> Rica Dodo Delmar Buchler </p>
        <p> Rua Jose Maria Lisboa, 480/62 - Jardim Paulista - </p>
        <p> 01423-908 - S&#227;o Paulo, SP - Brasil </p>
        <p> E-mail: </p>
        <p><email xlink:href="rdelmar@cardiol.br">rdelmar@cardiol.br</email>, </p>
        <p>
          <email xlink:href="jrbuchler@uol.com.br">jrbuchler@uol.com.br</email>
        </p>
      </fn>
    </p>
    <p>Artigo recebido em 20/05/09; revisado recebido em 04/04/10; aceito em 13/05/10.</p>
  </body>
  <back>
    <ref-list>
      <ref id="B1">
        <mixed-citation>1. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003; 361 (9351): 13-20.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials</article-title>
          <source>Lancet</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>13</fpage>
          <lpage>20</lpage>
          <issue>9351</issue>
          <volume>361</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Keeley</surname>
              <given-names>EC</given-names>
            </name>
            <name>
              <surname>Boura</surname>
              <given-names>JA</given-names>
            </name>
            <name>
              <surname>Grines</surname>
              <given-names>CL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B2">
        <mixed-citation>2. Spaulding C, Henry P, Teiger E, Bramucci E, Carri&#233; D, Slama MS, et al. Sirolimus-eluting versus uncoated stents in acute myocardial infarcyion. N Engl J Med. 2006; 355 (11): 1093-104.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Sirolimus-eluting versus uncoated stents in acute myocardial infarcyion</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>1093</fpage>
          <lpage>104</lpage>
          <issue>11</issue>
          <volume>355</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Spaulding</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Henry</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Teiger</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Bramucci</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Carri&#233;</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Slama</surname>
              <given-names>MS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B3">
        <mixed-citation>3. Stone GW, Grines CL, Cox DA, Garcia E, Tcheng JE, Griffin JJ, et al. Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002; 346 (13): 957-66.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators: Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>957</fpage>
          <lpage>66</lpage>
          <issue>13</issue>
          <volume>346</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Stone</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>Grines</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tcheng</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Griffin</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B4">
        <mixed-citation>4. Michaelides AP, Psomadaki ZD, Dilaveris PE, Richter DJ, Andrikopoulos GK, Aggeli KD, et al. Improved detection of coronary artery disease by exercise electrocardiography with the use of right precordial leads. N Engl J Med. 1999; 340 (5): 340-5.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Improved detection of coronary artery disease by exercise electrocardiography with the use of right precordial leads</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>340</fpage>
          <lpage>5</lpage>
          <issue>5</issue>
          <volume>340</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Michaelides</surname>
              <given-names>AP</given-names>
            </name>
            <name>
              <surname>Psomadaki</surname>
              <given-names>ZD</given-names>
            </name>
            <name>
              <surname>Dilaveris</surname>
              <given-names>PE</given-names>
            </name>
            <name>
              <surname>Richter</surname>
              <given-names>DJ</given-names>
            </name>
            <name>
              <surname>Andrikopoulos</surname>
              <given-names>GK</given-names>
            </name>
            <name>
              <surname>Aggeli</surname>
              <given-names>KD</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B5">
        <mixed-citation>5. Giedd KN, Bergmann SR. Myocardial perfusion imaging following percutaneous coronary intervention: the importance of restenosis disease progression, and directed reintervention. J Am Coll Cardiol. 2004; 43 (3): 328-36.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myocardial perfusion imaging following percutaneous coronary intervention: the importance of restenosis disease progression, and directed reintervention</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>328</fpage>
          <lpage>36</lpage>
          <issue>3</issue>
          <volume>43</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Giedd</surname>
              <given-names>KN</given-names>
            </name>
            <name>
              <surname>Bergmann</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B6">
        <mixed-citation>6. Killip T 3rd, Kimball JT. Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients. Am J Cardiol. 1967; 20 (4): 457-64.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Treatment of myocardial infarction in a coronary care unit: a two year experience with 250 patients</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1967</year>
          </date>
          <fpage>457</fpage>
          <lpage>64</lpage>
          <issue>4</issue>
          <volume>20</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Killip 3rd</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Kimball</surname>
              <given-names>JT</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B7">
        <mixed-citation>7. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, Jacobs AK, Kern MJ, King SB 3rd, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol. 2006; 47 (1): e1-121.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>American College of Cardiology/American Heart Association Task Force on Practice Guidelines; ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention: ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention)</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>e1</fpage>
          <lpage>121</lpage>
          <issue>1</issue>
          <volume>47</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Smith Jr</surname>
              <given-names>SC</given-names>
            </name>
            <name>
              <surname>Feldman</surname>
              <given-names>TE</given-names>
            </name>
            <name>
              <surname>Hirshfeld Jr</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Jacobs</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Kern</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>King 3rd</surname>
              <given-names>SB</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B8">
        <mixed-citation>8. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med. 1985; 312 (14): 932-6.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Phase I findings: TIMI Study Group</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1985</year>
          </date>
          <fpage>932</fpage>
          <lpage>6</lpage>
          <issue>14</issue>
          <volume>312</volume>
        </element-citation>
      </ref>
      <ref id="B9">
        <mixed-citation>9. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18 (12): 1440-63.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography: Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology</article-title>
          <source>J Am Soc Echocardiogr</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>1440</fpage>
          <lpage>63</lpage>
          <issue>12</issue>
          <volume>18</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Lang</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Bierig</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Devereux</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Flachskampf</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Foster</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Pellikka</surname>
              <given-names>PA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B10">
        <mixed-citation>10. Balady GJ, Berra KA, Golding LA, Gordon NF, Mahler DA. ACSMs Guidelines for exercise testing and prescription. 6th ed. Baltimore, Maryland, U.S.A: Lippincott, Williams and Wilkins; 2000. p. 97-8.</mixed-citation>
        <element-citation publication-type="book">
          <source>ACSMs Guidelines for exercise testing and prescription</source>
          <date>
            <year>2000</year>
          </date>
          <person-group person-group-type="author">
            <name>
              <surname>Balady</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Berra</surname>
              <given-names>KA</given-names>
            </name>
            <name>
              <surname>Golding</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Gordon</surname>
              <given-names>NF</given-names>
            </name>
            <name>
              <surname>Mahler</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B11">
        <mixed-citation>11. Gibbons RJ, Balady GJ, Bricker JT, Chaitman BR, Fletcher GF, Froelicher VF, et al. American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation. 2002; 106 (14): 1883-92.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines): ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines)</article-title>
          <source>Circulation</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>1883</fpage>
          <lpage>92</lpage>
          <issue>14</issue>
          <volume>106</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Gibbons</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Balady</surname>
              <given-names>GJ</given-names>
            </name>
            <name>
              <surname>Bricker</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Chaitman</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Fletcher</surname>
              <given-names>GF</given-names>
            </name>
            <name>
              <surname>Froelicher</surname>
              <given-names>VF</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B12">
        <mixed-citation>12. Bruce RA, Kusumi F, Hosmer D. Maximal oxygen intake and normographic assessment of functional aerobic impairment in cardiovascular disease. Am Heart J. 1973; 85 (4): 546-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Maximal oxygen intake and normographic assessment of functional aerobic impairment in cardiovascular disease</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1973</year>
          </date>
          <fpage>546</fpage>
          <lpage>62</lpage>
          <issue>4</issue>
          <volume>85</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bruce</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Kusumi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hosmer</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B13">
        <mixed-citation>13. Mark DB, Shaw L, Harrell FE Jr, Hlatky MA, Lee KL, Bengtson JR, et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N Engl J Med. 1991; 325 (12): 849-53.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1991</year>
          </date>
          <fpage>849</fpage>
          <lpage>53</lpage>
          <issue>12</issue>
          <volume>325</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Mark</surname>
              <given-names>DB</given-names>
            </name>
            <name>
              <surname>Shaw</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Harrell Jr</surname>
              <given-names>FE</given-names>
            </name>
            <name>
              <surname>Hlatky</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>KL</given-names>
            </name>
            <name>
              <surname>Bengtson</surname>
              <given-names>JR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B14">
        <mixed-citation>14. Berman DS, Kiat H, Friedman JD, Wang FP, van Train K, Matzer L, et al. Separate acquisition rest thallium-201/stress technetium-99m sestamibi dual-isotope myocardial perfusion single photon emission computed tomography: a clinical validation study. J Am Coll Cardiol. 1993; 22 (5): 1455-64.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Separate acquisition rest thallium-201/stress technetium-99m sestamibi dual-isotope myocardial perfusion single photon emission computed tomography: a clinical validation study</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1993</year>
          </date>
          <fpage>1455</fpage>
          <lpage>64</lpage>
          <issue>5</issue>
          <volume>22</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Berman</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Kiat</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>FP</given-names>
            </name>
            <name>
              <surname>van Train</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Matzer</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B15">
        <mixed-citation>15. Acampa W, Petretta M, Florimonte L, Mattera A, Cuocolo A. Prognostic value of exercise cardiac tomography performed late after percutaneous coronary intervention in symptomatic and symptom free patients. Am J Cardiol. 2003; 91 (3): 259-63.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Prognostic value of exercise cardiac tomography performed late after percutaneous coronary intervention in symptomatic and symptom free patients</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>259</fpage>
          <lpage>63</lpage>
          <issue>3</issue>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Acampa</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Petretta</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Florimonte</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mattera</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cuocolo</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B16">
        <mixed-citation>16. Grines CL, Cox DA, Stone GW, Garcia E, Mattos LA, Giambartolomei A, et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent Primary Angioplasty in Myocardial Infarction Study Group. N Engl J Med. 1999; 341 (26): 1949-56.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Coronary angioplasty with or without stent implantation for acute myocardial infarction: Stent Primary Angioplasty in Myocardial Infarction Study Group</article-title>
          <source>N Engl J Med</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>1949</fpage>
          <lpage>56</lpage>
          <issue>26</issue>
          <volume>341</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Grines</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Cox</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Stone</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>Garcia</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Mattos</surname>
              <given-names>LA</given-names>
            </name>
            <name>
              <surname>Giambartolomei</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B17">
        <mixed-citation>17. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977; 33 (1): 159-74.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The measurement of observer agreement for categorical data</article-title>
          <source>Biometrics</source>
          <date>
            <year>1977</year>
          </date>
          <fpage>159</fpage>
          <lpage>74</lpage>
          <issue>1</issue>
          <volume>33</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Landis</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Koch</surname>
              <given-names>GG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B18">
        <mixed-citation>18. Stone GW, Brodie BR, Griffin JJ, Costantini C, Morice MC, St Goar FG, et al. Clinical and angiographic follow-up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction(PAMI) stent pilot trial. Circulation. 1999; 99 (12): 1548-54.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical and angiographic follow-up after primary stenting in acute myocardial infarction: the Primary Angioplasty in Myocardial Infarction(PAMI) stent pilot trial</article-title>
          <source>Circulation</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>1548</fpage>
          <lpage>54</lpage>
          <issue>12</issue>
          <volume>99</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Stone</surname>
              <given-names>GW</given-names>
            </name>
            <name>
              <surname>Brodie</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Griffin</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Costantini</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Morice</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>St Goar</surname>
              <given-names>FG</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B19">
        <mixed-citation>19. Cutlip DE, Chauhan MS, Baim DS, Ho KK, Popma JJ, Carrozza JP, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002; 40 (12): 2082-9.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2002</year>
          </date>
          <fpage>2082</fpage>
          <lpage>9</lpage>
          <issue>12</issue>
          <volume>40</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Cutlip</surname>
              <given-names>DE</given-names>
            </name>
            <name>
              <surname>Chauhan</surname>
              <given-names>MS</given-names>
            </name>
            <name>
              <surname>Baim</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Ho</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Popma</surname>
              <given-names>JJ</given-names>
            </name>
            <name>
              <surname>Carrozza</surname>
              <given-names>JP</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B20">
        <mixed-citation>20. Rodriguez A, Bernardi V, Fernandez M, Mauvecin C, Ayala F, Santaera O, et al. In-hospital and late results of coronary stents versus conventional balloon angioplasty in acute myocardial infarction (GRAMI trial). Gianturco-Roubin in Acute Myocardial Infarction. Am J Cardiol. 1998; 81 (11): 1286-91.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>In-hospital and late results of coronary stents versus conventional balloon angioplasty in acute myocardial infarction (GRAMI trial): Gianturco-Roubin in Acute Myocardial Infarction</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1286</fpage>
          <lpage>91</lpage>
          <issue>11</issue>
          <volume>81</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rodriguez</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Bernardi</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Fernandez</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Mauvecin</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Ayala</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Santaera</surname>
              <given-names>O</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B21">
        <mixed-citation>21. Maillard L, Hamon M, Khalife K, Steg PG, Beygui F, Guermonprez JL, et al. A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction. STENTIM-2 Investigators. J Am Coll Cardiol. 2000; 35 (7): 1729-36.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>A comparison of systematic stenting and conventional balloon angioplasty during primary percutaneous transluminal coronary angioplasty for acute myocardial infarction: STENTIM-2 Investigators</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1729</fpage>
          <lpage>36</lpage>
          <issue>7</issue>
          <volume>35</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Maillard</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hamon</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Khalife</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Steg</surname>
              <given-names>PG</given-names>
            </name>
            <name>
              <surname>Beygui</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Guermonprez</surname>
              <given-names>JL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B22">
        <mixed-citation>22. Zhu MM, Feit A, Chadow H, Alam M, Kwan T, Clark LT. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials. Am J Cardiol. 2001; 88 (3): 297-301.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-analysis of randomized clinical trials</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>297</fpage>
          <lpage>301</lpage>
          <issue>3</issue>
          <volume>88</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Zhu</surname>
              <given-names>MM</given-names>
            </name>
            <name>
              <surname>Feit</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Chadow</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Alam</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kwan</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Clark</surname>
              <given-names>LT</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B23">
        <mixed-citation>23. Rosanio S, Tocchi M, Stouffer GA. Use of stress testing to evaluate patients with recurrent chest pain after percutaneous coronary revacularization. Am J Med Sci. 1998; 316 (1): 46-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Use of stress testing to evaluate patients with recurrent chest pain after percutaneous coronary revacularization</article-title>
          <source>Am J Med Sci</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>46</fpage>
          <lpage>52</lpage>
          <issue>1</issue>
          <volume>316</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rosanio</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tocchi</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Stouffer</surname>
              <given-names>GA</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B24">
        <mixed-citation>24. Laarman G, Luijten HE, van Zeyl LG, Beatt KJ, Tijssen JG, Serruys PW, et al. Assessment of "silent" restenosis and long term follow- up after successful angioplasty in single vessel coronary artery disease : the value of quantitative exercise electrocardiography and quantitative coronary angiography. J Am Coll Cardiol. 1990; 16 (3): 578-85.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Assessment of "silent" restenosis and long term follow- up after successful angioplasty in single vessel coronary artery disease: the value of quantitative exercise electrocardiography and quantitative coronary angiography</article-title>
          <source>J Am Coll Cardiol</source>
          <date>
            <year>1990</year>
          </date>
          <fpage>578</fpage>
          <lpage>85</lpage>
          <issue>3</issue>
          <volume>16</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Laarman</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Luijten</surname>
              <given-names>HE</given-names>
            </name>
            <name>
              <surname>van Zeyl</surname>
              <given-names>LG</given-names>
            </name>
            <name>
              <surname>Beatt</surname>
              <given-names>KJ</given-names>
            </name>
            <name>
              <surname>Tijssen</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Serruys</surname>
              <given-names>PW</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B25">
        <mixed-citation>25. Dori G, Denekamp Y, Fishman S, Biherman H. Exercise stress testing, myocardial perfusion imaging and stress echocardiography for detecting restenosis after successful percutaneous transluminal coronary angioplasty: a review of performance. J Intern Med. 2003; 253 (3): 253-62.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise stress testing, myocardial perfusion imaging and stress echocardiography for detecting restenosis after successful percutaneous transluminal coronary angioplasty: a review of performance</article-title>
          <source>J Intern Med</source>
          <date>
            <year>2003</year>
          </date>
          <fpage>253</fpage>
          <lpage>62</lpage>
          <issue>3</issue>
          <volume>253</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dori</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Denekamp</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fishman</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Biherman</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B26">
        <mixed-citation>26. Koenig W, Ernst E. Exercise and thrombosis. Coron Artery Dis. 2000; 11 (2): 123-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Exercise and thrombosis</article-title>
          <source>Coron Artery Dis</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>123</fpage>
          <lpage>7</lpage>
          <issue>2</issue>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Koenig</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Ernst</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B27">
        <mixed-citation>27. Samuels B, Schumann J, Kiat H, Friedman J, Berman DS. Acute stent thrombosis associated with exercise testing after successful percutaneous transluminal coronary angioplasty. Am Heart J. 1995; 130 (5): 1120-2.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Acute stent thrombosis associated with exercise testing after successful percutaneous transluminal coronary angioplasty</article-title>
          <source>Am Heart J</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>1120</fpage>
          <lpage>2</lpage>
          <issue>5</issue>
          <volume>130</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Samuels</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Schumann</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kiat</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Friedman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Berman</surname>
              <given-names>DS</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B28">
        <mixed-citation>28. MeurinP, DomniezT, Weber H, Tournadre P, Elhadad S, Bourmayan C, et al. Occlusion of a coronary endoprosthesis after a negative stress test. Arch Mal Coeur Vaiss. 1999; 92 (3): 369-72.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Occlusion of a coronary endoprosthesis after a negative stress test</article-title>
          <source>Arch Mal Coeur Vaiss</source>
          <date>
            <year>1999</year>
          </date>
          <fpage>369</fpage>
          <lpage>72</lpage>
          <issue>3</issue>
          <volume>92</volume>
          <person-group person-group-type="author">
            <name>
              <surname>MeurinP</surname>
            </name>
            <name>
              <surname>DomniezT</surname>
            </name>
            <name>
              <surname>Weber</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Tournadre</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Elhadad</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bourmayan</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B29">
        <mixed-citation>29. Garz&#243;n P, Eisenberg MJ. Functional testing for the detection of restenosis after percutaneous transluminal coronary angioplasty: a meta-analysis. Can J Cardiol. 2001; 17 (1): 41-8.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Functional testing for the detection of restenosis after percutaneous transluminal coronary angioplasty: a meta-analysis</article-title>
          <source>Can J Cardiol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>41</fpage>
          <lpage>8</lpage>
          <issue>1</issue>
          <volume>17</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Garz&#243;n</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Eisenberg</surname>
              <given-names>MJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B30">
        <mixed-citation>30. Eisenberg MJ, Blankenship JC, Huynh T, Azrin M, Pathan A, Sedlis S, et al. Evaluation of routine functional testing after percutaneous coronary intervention. Am J Cardiol. 2004; 93 (6): 744-7.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Evaluation of routine functional testing after percutaneous coronary intervention</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2004</year>
          </date>
          <fpage>744</fpage>
          <lpage>7</lpage>
          <issue>6</issue>
          <volume>93</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Eisenberg</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Blankenship</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Huynh</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Azrin</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Pathan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sedlis</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B31">
        <mixed-citation>31. Galassi AR, Foti R, Azzarelli S, Coco G, Condorelli G, Russo G, et al. Usefulness of exercise tomographic myocardial perfusion imaging for detection of restenosis after coronary stent implantation. Am J Cardiol. 2000; 85 (11): 1362-4.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Usefulness of exercise tomographic myocardial perfusion imaging for detection of restenosis after coronary stent implantation</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1362</fpage>
          <lpage>4</lpage>
          <issue>11</issue>
          <volume>85</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Galassi</surname>
              <given-names>AR</given-names>
            </name>
            <name>
              <surname>Foti</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Azzarelli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Coco</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Condorelli</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Russo</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B32">
        <mixed-citation>3. Bokhari S, Blook DK, Bergmann SR. Failure of right precordial electrocardiography during stress testing to identify coronary artery disease. J Nucl Cardiol. 2001; 8 (3): 325-31.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Failure of right precordial electrocardiography during stress testing to identify coronary artery disease</article-title>
          <source>J Nucl Cardiol</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>325</fpage>
          <lpage>31</lpage>
          <issue>3</issue>
          <volume>8</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bokhari</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Blook</surname>
              <given-names>DK</given-names>
            </name>
            <name>
              <surname>Bergmann</surname>
              <given-names>SR</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B33">
        <mixed-citation>33. Bainey KR, Kalia N, Carter D, Hrynchyshyn G, Kasza L, Lee TK, et al. Right precordial leads and lead aVR at exercise electrocardiography: does it change test results? Ann Noninvasive Electrocardiol. 2006; 11 (3): 247-52.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Right precordial leads and lead aVR at exercise electrocardiography: does it change test results?</article-title>
          <source>Ann Noninvasive Electrocardiol</source>
          <date>
            <year>2006</year>
          </date>
          <fpage>247</fpage>
          <lpage>52</lpage>
          <issue>3</issue>
          <volume>11</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Bainey</surname>
              <given-names>KR</given-names>
            </name>
            <name>
              <surname>Kalia</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Carter</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hrynchyshyn</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kasza</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>TK</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B34">
        <mixed-citation>34. Dutcher JR, Kahn J, Grines C, Franklin B. Comparison of left ventricular ejection fraction and exercise capacity as predictors of two- and five-year mortality following acute myocardial infarction. Am J Cardiol. 2007; 99 (4): 436-41.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Comparison of left ventricular ejection fraction and exercise capacity as predictors of two- and five-year mortality following acute myocardial infarction</article-title>
          <source>Am J Cardiol</source>
          <date>
            <year>2007</year>
          </date>
          <fpage>436</fpage>
          <lpage>41</lpage>
          <issue>4</issue>
          <volume>99</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Dutcher</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Kahn</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Grines</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Franklin</surname>
              <given-names>B</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B35">
        <mixed-citation>35. Valeur N, Clemmensen P, Saunamaki K, Grande P. (DANAMI-2 investigators). The prognostic value of pre-discharge exercise testing after myocardial infarction treated with either primary PCI or fibrinolysis: a DANAMI-2 sub-study. Eur Heart J. 2005; 26 (2): 119-27.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The prognostic value of pre-discharge exercise testing after myocardial infarction treated with either primary PCI or fibrinolysis: a DANAMI-2 sub-study</article-title>
          <source>Eur Heart J</source>
          <date>
            <year>2005</year>
          </date>
          <fpage>119</fpage>
          <lpage>27</lpage>
          <issue>2</issue>
          <volume>26</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Valeur</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Clemmensen</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Saunamaki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Grande</surname>
              <given-names>P</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B36">
        <mixed-citation>36. Ritchie J,Bateman TM, Bonow RO, Crawford MH, Gibbons RJ, Hall RJ, et al. Guidelines for clinical use cardiac radionuclide imaging. A report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures, (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology. Circulation. 1995; 91 (4): 1278-303.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Guidelines for clinical use cardiac radionuclide imaging: A report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures, (Committee on Radionuclide Imaging), developed in collaboration with the American Society of Nuclear Cardiology</article-title>
          <source>Circulation</source>
          <date>
            <year>1995</year>
          </date>
          <fpage>1278</fpage>
          <lpage>303</lpage>
          <issue>4</issue>
          <volume>91</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Ritchie</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bateman</surname>
              <given-names>TM</given-names>
            </name>
            <name>
              <surname>Bonow</surname>
              <given-names>RO</given-names>
            </name>
            <name>
              <surname>Crawford</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Gibbons</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Hall</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B37">
        <mixed-citation>37. Rodes-Cabau J, Candell-Riera J, Domingo E, Castell-Conesa J, Anivarro I, Angel J, et al. Frequency and clinical significance of myocardial ischemia detected early after coronary stent implantation. J Nucl Med. 2001; 42 (12): 1768-72.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Frequency and clinical significance of myocardial ischemia detected early after coronary stent implantation</article-title>
          <source>J Nucl Med</source>
          <date>
            <year>2001</year>
          </date>
          <fpage>1768</fpage>
          <lpage>72</lpage>
          <issue>12</issue>
          <volume>42</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Rodes-Cabau</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Candell-Riera</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Domingo</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Castell-Conesa</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Anivarro</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Angel</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B38">
        <mixed-citation>38. Isaaz K, Afif Z, Prevot N, Cerisier A, Lamaud M, Richard L, et al.The value of stress single-photon emission computed tomography imaging performed routinely at 6 months in asymptomatic patients for predicting angiographic restenosis after successful direct percutaneous intervention for acute ST elevation myocardial infarction.Coron Artery Dis. 2008; 19 (2): 89-97.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>The value of stress single-photon emission computed tomography imaging performed routinely at 6 months in asymptomatic patients for predicting angiographic restenosis after successful direct percutaneous intervention for acute ST elevation myocardial infarction</article-title>
          <source>Coron Artery Dis</source>
          <date>
            <year>2008</year>
          </date>
          <fpage>89</fpage>
          <lpage>97</lpage>
          <issue>2</issue>
          <volume>19</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Isaaz</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Afif</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Prevot</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Cerisier</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lamaud</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Richard</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B39">
        <mixed-citation>39. Kosa I, Blasini R, Schneider-Eicke J, Neumann FJ, Matsunari I, Neverve J, et al. Myocardial perfusion scintigraphy to evaluate patients after coronary stent implantation. J Nucl Med. 1998; 39 (8): 1307-11.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Myocardial perfusion scintigraphy to evaluate patients after coronary stent implantation</article-title>
          <source>J Nucl Med</source>
          <date>
            <year>1998</year>
          </date>
          <fpage>1307</fpage>
          <lpage>11</lpage>
          <issue>8</issue>
          <volume>39</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Kosa</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Blasini</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Schneider-Eicke</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Neumann</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Matsunari</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Neverve</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
      <ref id="B40">
        <mixed-citation>40. Beller GA, Zaret BL. Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease. Circulation. 2000; 101 (12): 1465-78.</mixed-citation>
        <element-citation publication-type="journal">
          <article-title>Contributions of nuclear cardiology to diagnosis and prognosis of patients with coronary artery disease</article-title>
          <source>Circulation</source>
          <date>
            <year>2000</year>
          </date>
          <fpage>1465</fpage>
          <lpage>78</lpage>
          <issue>12</issue>
          <volume>101</volume>
          <person-group person-group-type="author">
            <name>
              <surname>Beller</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Zaret</surname>
              <given-names>BL</given-names>
            </name>
          </person-group>
        </element-citation>
      </ref>
    </ref-list>
  </back>
  <sub-article article-type="translation" id="TRes" xml:lang="es">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Art&#237;culos Originales</subject>
        </subj-group>
      </article-categories>
      <title-group/>
    </front-stub>
    <body>
      <p>
        <bold>ART&#205;CULO ORIGINAL</bold>
      </p>
      <p>
        <fn id="top-body2">
          <label>
            <bold>Evaluaci&#243;n no invasiva de pacientes sometidos a intervenci&#243;n percut&#225;nea en el infarto de miocardio</bold>
          </label>
          <p>
            <bold>Rica Dodo Delmar Buchler; Expedito E. Ribeiro; Antonio de Padua Mansur; Paola Smanio; Romeu Sergio Meneghelo; William Azem Chalela; Carlos Alberto Buchpiguel; Jorge Roberto Buchler; Eric R. Bates; Eulogio E. Martinez</bold>
          </p>
        </fn>
      </p>
      <p>Instituto do Cora&#231;&#227;o (InCor) da Faculdade de Medicina da Universidade de S&#227;o Paulo, Instituto Dante Pazzanese de Cardiologia, University Of Michigan - AnnArbor - Michigan</p>
      <p>Correspondencia</p>
      <p>
        <bold>RESUMEN</bold>
      </p>
      <p><bold>FUNDAMENTO:</bold> La reestenosis postintervenci&#243;n coronaria percut&#225;nea primaria sigue siendo un problema de relevancia cl&#237;nica, incluso con la implantaci&#243;n del stent. La capacidad de las pruebas no invasivas para la detecci&#243;n de reestenosis no se demostr&#243; totalmente.</p>
      <p><bold>OBJETIVO:</bold> Evaluar la habilidad de la prueba ergom&#233;trica (PE) y de la gammagraf&#237;a de perfusi&#243;n mioc&#225;rdica (GPM) en el diagn&#243;stico de reestenosis en pacientes con infarto agudo de miocardio, y supradesnivelaci&#243;n del segmento ST, sometidos a la angioplastia coronaria percut&#225;nea primaria (ACPP), con implantaci&#243;n de stent en las primeras 12 horas de evoluci&#243;n.</p>
      <p><bold>M&#201;TODOS:</bold> Desde Ago/2003-Ene/2006, se seleccionaron a 64 pacientes (ps) (56,2 &#177; 10,2 a&#241;os, 53 hombres) sometidos a ACPP. Se incluyeron solamente a ps con fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo <underline>&gt;</underline> 40,0%, definida por ecocardiograf&#237;a de reposo. Prueba ergom&#233;trica, con las 12 derivaciones del ECG asociadas a precordiales derechas, y GPM se realizaron en 6 semanas, 6 meses y un a&#241;o despu&#233;s del tratamiento. La cinecoronariograf&#237;a se realiz&#243; en el 6&#186; mes.</p>
      <p><bold>RESULTADOS:</bold> La enfermedad uniarterial se produjo en un 46,9% de los ps, y la arteria descendente anterior se trat&#243; en el 48,4%. La reestenosis angiogr&#225;fica se produjo en un 28,8%. Sensibilidad, especificidad, valor predictivo positivo (VPP), valor predictivo negativo (VPN) y exactitud del para PE para la detecci&#243;n de reestenosis no fueron significativas. La adici&#243;n de derivaciones precordiales derechas no proporcion&#243; informaciones adicionales. Sensibilidad, especificidad, VPP, VPN y precisi&#243;n de la GPM presentaron correlaci&#243;n con reestenosis solamente en el 6&#186; mes, teniendo en cuenta <italic>summed difference score</italic> &gt; 2 (p = 0,006) y &gt; 4 (p = 0,014).</p>
      <p><bold>CONCLUSI&#211;N:</bold> El PE en el discrimin&#243; reestenosis. La GPM llev&#243; a cabo en el 6&#186; mes se relacion&#243; con la reestenosis y mostr&#243; &#250;til durante la evoluci&#243;n. (Arq Bras Cardiol 2010;95(5):555-562)</p>
      <p><bold>Palabras-clave:</bold> Reestenosis coronaria, angioplastia, <italic>stent</italic>, infarto de miocardio, procedimientos cl&#237;nicos.</p>
      <p>
        <bold>Introducci&#243;n</bold>
      </p>
      <p>La angioplastia coronaria percut&#225;nea primaria (ACCP) es superior al tratamiento fibrinol&#237;tico en el tratamiento del infarto agudo de miocardio con supradesnivelaci&#243;n del segmento ST<sup>1</sup>. Debido a los elevados &#237;ndices de reestenosis, los stents coronarios surgieron como nueva estrategia, sin embargo la reestenosis sigue siendo un factor limitante, con &#237;ndices entre un 20% y un 25%<sup>2,3</sup>, cuando utilizados stents sin eluci&#243;n de medicamentos.</p>
      <p>La puesta en pr&#225;ctica adecuada de las pruebas no invasivas despu&#233;s de ACPP no se ha investigado sistem&#225;ticamente. De entre las pruebas no invasivas, la prueba de esfuerzo (PE) y la gammagraf&#237;a de perfusi&#243;n mioc&#225;rdica (GPM) se vienen utilizando para identificar la reestenosis. La PE es segura, sencilla y f&#225;cil de llevarse a cabo. La adici&#243;n de las derivaciones precordiales derechas se vienen adoptando para mejorar la sensibilidad de PE<sup>4</sup>. Por otra parte, la sensibilidad de la GPM para la identificaci&#243;n de reestenosis puede variar entre el 39% y el 100% y el 46% y el 100%, respectivamente, adem&#225;s de aumentar con el tiempo transcurrido despu&#233;s de la revascularizaci&#243;n<sup>5</sup>.</p>
      <p>El objetivo de este estudio fue determinar el valor pron&#243;stico de la PE y la GPM en la detecci&#243;n de reestenosis <italic>intrastent</italic> durante el seguimiento cl&#237;nico despu&#233;s de la ACPP.</p>
      <p>
        <bold>Materiales y m&#233;todos</bold>
      </p>
      <p>La angioplastia primaria con implantaci&#243;n de stent durante la fase aguda del infarto del miocardio se condujo en dos centros por operadores experimentados. Los pacientes realizaron la PE y GPM a las 6 semanas, despu&#233;s a los 6 meses y, por &#250;ltimo, un a&#241;o despu&#233;s de la intervenci&#243;n. Las PE se realizaron en la vigencia de la medicaci&#243;n prescripta, incluidos los betabloqueantes. La cineangiocoronariograf&#237;a se llev&#243; a cabo durante el 6&#186; mes de evoluci&#243;n. El ecocardiograma transtor&#225;cico con el paciente en reposo se realiz&#243; antes de la dada de alta hospitalaria, a fin de evaluar la fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo (FEVI) para inclusi&#243;n del paciente en el protocolo.</p>
      <p>El estudio fue aprobado por los Comit&#233;s de &#201;tica de ambas las Instituciones y todos los pacientes firmaron el formulario de consentimiento informado. El estudio se llev&#243; a cabo de conformidad con los principios cl&#237;nicos de la declaraci&#243;n de Helsinki para investigaciones en seres humanos.</p>
      <p>
        <bold>Poblaci&#243;n o casu&#237;stica</bold>
      </p>
      <p>Durante el per&#237;odo comprendido entre ago/2003 y ene/2006, en el seguimiento prospectivo, se seleccionaron a 80 pacientes con infarto agudo de miocardio con supradesnivelaci&#243;n del segmento ST tratados por angioplastia coronaria primaria con implantaci&#243;n de stent durante las primeras 12 horas de evoluci&#243;n, en el Instituto do Cora&#231;&#227;o de la FMUSP-InCor y en el Instituto Dante Pazzanese de Cardiolog&#237;a en S&#227;o Paulo. Los criterios de inclusi&#243;n fueron: edad <underline>&lt;</underline> 75 a&#241;os, ausencia de infarto previo, clase Killip 1&#186;, FEVI <underline>&gt;</underline> 40% evaluado por ecocardiograf&#237;a transtor&#225;cica en reposo y capacidad de realizar prueba ergom&#233;trica en cinta rodante.</p>
      <p>Los Stents sin eluci&#243;n de medicamentos se utilizaron en todos los pacientes. Diecis&#233;is pacientes (20,0%) fueron excluidos: 5 porque no cumpl&#237;an los criterios ecocardiogr&#225;ficos de elegibilidad, 11 por no completar el protocolo de estudio hasta el final. Por lo tanto, 64 pacientes fueron seguidos durante al menos un a&#241;o.</p>
      <p>Todas las intervenciones se realizaron de acuerdo con las directrices actuales, incluyendo inhibidores de la glucoprote&#237;na IIb/IIIa a criterio del operador<sup>7</sup>. Los criterios de &#233;xito angiogr&#225;fico fueron estenosis residual del vaso tratado <underline>&lt;</underline> 30% y presencia de flujo TIMI 3<sup>8</sup>. Solamente el vaso relacionado al infarto fue tratado.</p>
      <p>
        <bold>Protocolo del estudio o m&#233;todos</bold>
      </p>
      <p>
        <bold>Ecocardiogramas</bold>
      </p>
      <p>Los ex&#225;menes de ecocardiograf&#237;a Doppler se realizaron antes de la dada de alta hospitalaria, con equipos Ultramark -9 HDI de la marca ATL (<italic>Advanced Technology Laboratories Inc</italic>., Cherry Hills, NJ). El m&#233;todo de Simpson se utiliz&#243; para obtener FEVI<sup>9</sup>. Este examen defini&#243; la inclusi&#243;n y la posterior permanencia del paciente en el protocolo de estudio.</p>
      <p>
        <bold>Pruebas ergom&#233;tricas</bold>
      </p>
      <p>Todos los pacientes realizaron PE s&#237;ntoma limitante, de acuerdo con el protocolo de Bruce<sup>10</sup>, y gammagraf&#237;a de perfusi&#243;n mioc&#225;rdica con captaci&#243;n tomogr&#225;fica (SPECT), sincronizada al ECG (Gated-SPECT). La monitorizaci&#243;n se realiz&#243; con las 12 derivaciones del ECG asociadas a las derivaciones precordiales derechas, V3R, V4R y V5R con el fin de aumentar la sensibilidad y la especificidad de la prueba de esfuerzo. La PE se realiz&#243; acorde a las directrices previamente descriptas<sup>11</sup>. La capacidad funcional se evalu&#243; mediante la duraci&#243;n del ejercicio en minutos y por el n&#250;mero de METS alcanzado, con la aplicaci&#243;n de la ecuaci&#243;n descripta por Bruce<sup>12</sup> (un MET = 3,5 ml O<sub>2</sub>/kg/minuto).</p>
      <p>Se tom&#243; como criterio electrocardiogr&#225;fico de isquemia mioc&#225;rdica la presencia de infradesnivelaci&#243;n del segmento ST de morfolog&#237;a ascendente u horizontal <underline>&gt;</underline> 1 mm, 80 ms despu&#233;s del punto J en m&#225;s de tres complejos QRS consecutivos, en la presencia o no de dolor precordial. La infradesnivelaci&#243;n de morfolog&#237;a descendente se evalu&#243; en nivel de punto J. La angina se consider&#243; como un criterio cl&#237;nico de isquemia mioc&#225;rdica. La puntuaci&#243;n de Duke se calcul&#243;, de acuerdo con una f&#243;rmula previamente descrita<sup>13</sup>.</p>
      <p>En el pico del ejercicio, se inyectaron por v&#237;a endovenosa, en bolus, de 444 a 555 mBQ de sestamibi, marcados con tecn&#233;cio 99-m. Los pacientes continuaron a ejercitarse durante un minuto antes de parar el esfuerzo. Antes de la fase de ejercicio, la misma dosis de sestamibi se inyect&#243; en reposo. La gammagraf&#237;a se realiz&#243; de acuerdo con la t&#233;cnica de <italic>Gated SPECT</italic>, entre 60 y 90 minutos despu&#233;s de la inyecci&#243;n del radiof&#225;rmaco.</p>
      <p>
        <bold>La gammagraf&#237;a de perfusi&#243;n mioc&#225;rdica - Protocolo de adquisici&#243;n de las im&#225;genes</bold>
      </p>
      <p>Las adquisiciones se realizaron seg&#250;n la metodolog&#237;a descrita previamente<sup>14</sup>. El <italic>SPECT (Single Photon Emission Computed Tomography)</italic> se puso en pr&#225;ctica con gama c&#225;mara rotatoria (CardioMD, Philips Medical Systems, Milpitas, CA, USA) y las im&#225;genes se adquirieron con matriz 64 x 64 y ventana del 20% con fotopico en 140 keV se utiliz&#243;.</p>
      <p>La perfusi&#243;n del miocardio se evalu&#243; mediante el an&#225;lisis cualitativo y semicuantitativo. Para el an&#225;lisis cualitativo, la perfusi&#243;n se clasific&#243; como normal, isquemia transitoria (hipocaptaci&#243;n solamente en el esfuerzo), fibrosis o hipoperfusi&#243;n fija (hipocaptaci&#243;n en ambas fases) e hipoperfusi&#243;n fija y transitoria (coexistencia de tejido isqu&#233;mico y fibr&#243;tico, hipocaptaci&#243;n durante la fase de estr&#233;s y con mejora parcial durante la fase de reposo).</p>
      <p>Dos observadores independientes y expertos evaluaron las im&#225;genes. Para el an&#225;lisis semicuantitativo, el ventr&#237;culo izquierdo se dividi&#243; en 17 segmentos y los defectos de perfusi&#243;n se analizaron con la utilizaci&#243;n del sistema de scores de cero a 4:0 - captaci&#243;n normal; 1 - reducci&#243;n discreta de la perfusi&#243;n; 2 - disminuci&#243;n moderada de la perfusi&#243;n; 3 - reducci&#243;n acentuada de la perfusi&#243;n mioc&#225;rdica; y 4 - ausencia de captaci&#243;n del marcador.</p>
      <p>El <italic>Summed Stress Score</italic> se obtuvo con el sumatorio de los scores atribuidos a cada segmento derivado de las im&#225;genes obtenidas al esfuerzo (estr&#233;s f&#237;sico). El <italic>Summed Rest Score</italic> se obtuvo por el sumatorio de los scores atribuidos a cada segmento derivado de las im&#225;genes obtenidas en reposo. El <italic>Summed Difference Score,</italic> que representa la magnitud de la isquemia mioc&#225;rdica, se defini&#243; como la diferencia entre los scores de estr&#233;s y reposo<sup>15</sup> y se consider&#243; como defecto reversible cuando fue &gt; 2.</p>
      <p>El an&#225;lisis de todos los segmentos permiti&#243; identificar &#225;reas de isquemia relacionadas a vasos no tratados.</p>
      <p>
        <bold>Reestudio angiogr&#225;fico</bold>
      </p>
      <p>Todos los estudios se llevaron a cabo utilizando la t&#233;cnica de Judkins, 6 meses tras la ACPP, con cat&#233;teres 5 &#243; 6 French. La reestenosis intrastent se defini&#243; como lesi&#243;n cuando fue <underline>&gt;</underline> 50%, evaluada por angiograf&#237;a coronaria cuantitativa.</p>
      <p>
        <bold>Desenlaces</bold>
      </p>
      <p>Defunci&#243;n, infarto del miocardio o revascularizaci&#243;n del vaso tratado fueron considerados eventos mayores. El Infarto agudo de miocardio se defini&#243; seg&#250;n criterios previamente descritos<sup>16</sup>. Se consider&#243; como revascularizaci&#243;n del vaso blanco la repetici&#243;n del tratamiento (percut&#225;neo o quir&#250;rgico) resultante de lesi&#243;n ubicada en el vaso tratado.</p>
      <p>
        <bold>An&#225;lisis estad&#237;stico</bold>
      </p>
      <p>Las variables continuas se expresaron en una media y desviaci&#243;n est&#225;ndar y fueron comparadas utilizando la prueba t Student. Las variables categ&#243;ricas se describieron a trav&#233;s de frecuencias absolutas y relativas. &#205;ndices de sensibilidad, especificidad, valor predictivo positivo, valor predictivo negativo y precisi&#243;n se calcularon para PE y GPM, teniendo en cuenta los resultados del reestudio angiogr&#225;fico. Las asociaciones entre variables categ&#243;ricas se verificaron a trav&#233;s de las pruebas chi-cuadrado o prueba exacta de Fischer. La prueba t Student o la prueba no param&#233;trico de Mann-Whitney se utilizaron para variables continuas que no presentaron normalidad. El nivel de significancia se estableci&#243; en 0,05. La concordancia interobservadores para interpretaci&#243;n de las GPM se evalu&#243; seg&#250;n la medida estad&#237;stica Kappa.</p>
      <p>
        <bold>Resultados</bold>
      </p>
      <p>Las caracter&#237;sticas cl&#237;nicas de los pacientes se encontraron en la <xref ref-type="table" rid="tab1-body2">Tabla 1</xref>. El tiempo medio de dolor, desde el inicio de los s&#237;ntomas hasta la atenci&#243;n, fue de 4 horas, y el tiempo puerta-bal&#243;n fue de 75 minutos.</p>
      <table-wrap id="tab1-body2">
        <graphic xlink:href="1678-4170-abc-95-05-0555-00139-gt01-es.jpg"/></table-wrap>
      <p>
        <bold>Cinecoronariograf&#237;a</bold>
      </p>
      <p>La arteria descendente anterior fue tratada en 31 ps (48,4%), la arteria coronaria derecha en 22 (34,4%), la circunfleja en 7 (10,9%), el tronco de la arteria coronaria izquierda en dos (3,1%), la gran rama diagonal en una (1,56%) y la puente safena en una (1,56%) enfermedad multiarterial (otras lesiones coronarias <underline>&gt;</underline> 50%) se observ&#243; en 34 pacientes (53,1%). La revascularizaci&#243;n completa se realiz&#243; con &#233;xito en 30 ps con lesi&#243;n uniarterial y en tres pacientes con lesi&#243;n multiarterial previamente revascularizados. El di&#225;metro de referencia media del vaso pre y posprocedimiento fue de 2,9 &#177; 0,5 mm y 3,2 &#177; 0,4 mm, respectivamente. El di&#225;metro luminal m&#237;nimo pre y posprocedimiento fue respectivamente de 0,34 y 2,81 &#177; 0,4 mm &#177; 0,4 mm.</p>
      <p>El grado de estenosis pre y posprocedimiento fue del 87,7% &#177; 14,6% y 7,5% &#177; 4,2%, respectivamente.</p>
      <p>El estudio angiogr&#225;fico se realiz&#243; en 59/64 pacientes, tres antes de los 6 meses (uno de ellos, durante el tercer mes de evoluci&#243;n, debido a la angina y dos, durante el 4&#186; mes, debido al s&#237;ndrome coronario agudo). El reestenosis angiogr&#225;fico se produjo en 17 pacientes (28,8%), ocho con estenosis de 50% -70% y nueve con estenosis <underline>&gt;</underline> 70,0%. Una nueva revascularizaci&#243;n del vaso blanco se produjo en el 18,6% de los casos. El di&#225;metro de referencia final fue de 2,63 &#177; 0,72 mm y el di&#225;metro luminal m&#237;nimo fue de 1,95 &#177; 0,90 mm. La estenosis final media fue 39 &#177; 25%. No hubo diferencia en cuanto a la reestenosis en pacientes con enfermedad uni o multiarterial.</p>
      <p>
        <bold>Ecocardiogramas</bold>
      </p>
      <p>La FEVI media observada al examen llevado a cabo para inclusi&#243;n del paciente en el protocolo fue de 0,55.</p>
      <p>
        <bold>Pruebas ergom&#233;tricas</bold>
      </p>
      <p>Los ex&#225;menes se realizaron en vigencia terap&#233;utica prescripta tras la dada de alta hospitalaria. El uso de betabloqueantes estuvo presente en el 85%, el 79% y un 66,7% de los casos, durante las PE realizadas durante 6 semanas, 6 meses y 12 meses respectivamente. Clopidogrel o ticlopidina se prescribieron en un 45,9%, un 7,5% y un 7,5% respectivamente. Los datos de las pruebas ergom&#233;tricas seriadas se encuentran la <xref ref-type="table" rid="tab2-body2">Tabla 2</xref>.</p>
      <table-wrap id="tab2-body2">
        <graphic xlink:href="1678-4170-abc-95-05-0555-00139-gt02-es.jpg"/></table-wrap>
      <p>Los valores de sensibilidad, especificidad, VPP, VPN y precisi&#243;n de las PE, cuando comparados a los hallazgos en el reestudio angiogr&#225;fico, pueden ser observados en la <xref ref-type="table" rid="tab3-body2">Tabla 3</xref>. Cuando considerados los pacientes que alcanzaron el 85% de la frecuencia card&#237;aca m&#225;xima prevista, los &#237;ndices de sensibilidad, especificidad, valor predictivo positivo y valor predictivo negativo y precisi&#243;n para la detecci&#243;n de reestenosis fueron un 63,6%, un 67,7%, un 41,2%, el 84% y un 66,7%, respectivamente, con 6 semanas (p = 0,086); un 55,6%, un 83,3%, un 55,6%, un 83,3% y un 75,7%, a los 6 meses (p = 0,073); y el 40%, un 66,7%, un 30,8%, el 75% y un 59,4%, a los 12 meses despu&#233;s del tratamiento del infarto (p = 0,716).</p>
      <table-wrap id="tab3-body2">
        <graphic xlink:href="1678-4170-abc-95-05-0555-00139-gt03-es.jpg"/></table-wrap>
      <p>No hubo correlaci&#243;n entre reestenosis y la puntuaci&#243;n de Duke, tiempo de ejercicio, angina al esfuerzo, depresi&#243;n del segmento ST o cambios en derivaciones precordiales derechas. Encontramos mayor tiempo de ejercicio entre la primera y la segunda PE (p = 0,004) y entre la primera y la tercera PE (p = 0,004) en los 46 ps que llevaron a cabo tres ensayos consecutivos. Lo mismo se observ&#243; para los METS alcanzados (p = 0,002 y p = 0,004, respectivamente).</p>
      <p>
        <bold>Gammagraf&#237;a mioc&#225;rdica</bold>
      </p>
      <p>Los resultados del an&#225;lisis cualitativo se pueden observar en la <xref ref-type="table" rid="tab4-body2">Tabla 4</xref>.</p>
      <table-wrap id="tab4-body2">
        <graphic xlink:href="1678-4170-abc-95-05-0555-00139-gt04-es.jpg"/></table-wrap>
      <p>El an&#225;lisis semicuantitativo consider&#243; como isquemia transitoria el <italic>Summed Difference Score</italic> &gt; 2, y para la misma casu&#237;stica, se evalu&#243; asimismo la puntuaci&#243;n &gt; 4; los datos resultantes de este an&#225;lisis est&#225;n en la <xref ref-type="table" rid="es_a01tab05m-body2">Tabla 5</xref>. El an&#225;lisis interobservadores fue significativamente concordante, con medida Kappa = 0,762 (95% IC, 0,51- 1,0) p &lt; 0,001<sup>17</sup>.</p>
      <p content-type="asset">
        <table-wrap id="es_a01tab05m-body2">
          <graphic xlink:href="1678-4170-abc-95-05-0555-00139-gt05-es.jpg"/></table-wrap>
      </p>
      <p>El <italic>Summed Difference Score</italic> durante el primer a&#241;o, en 46 pacientes que llevaron a cabo todas las GPM secuenciales, no evidenci&#243; &#237;ndices estad&#237;sticamente significativos (p = 0,194). La comparaci&#243;n entre los <italic>Summed Difference Score</italic> observados 6 semanas, 6 meses y un a&#241;o tras la ACPP y la reestenosis no alcanz&#243; significancia (p = 0,056). Los <italic>Summed Stress Scores</italic> y los <italic>Summed Rest Scores</italic> fueron comparados con reestenosis en todas las GPM y fueron subdivididos en 0 a 4, 4 a 8 y &gt;8, de acuerdo con la extensi&#243;n del miocardio afectado. Hubo correlaci&#243;n entre la extensi&#243;n de miocardio afectado y reestenosis en el examen de un a&#241;o, en reposo (p = 0,0019) y tras estr&#233;s f&#237;sico (p = 0,004).</p>
      <p>
        <bold>Evoluci&#243;n</bold>
      </p>
      <p>La Reestenosis angiogr&#225;fica se produjo en 17/59 pacientes (28,8%). Trombosis subaguda del <italic>stent</italic> se observ&#243; en un paciente, 27 d&#237;as despu&#233;s de la ACPP. El s&#237;ndrome coronario agudo sin supradenivelaci&#243;n del segmento ST se produjo en dos pacientes durante el 4 &#186; mes (uno de ellos fue tratado con revascularizaci&#243;n quir&#250;rgica y otro por la angioplastia con bal&#243;n). La reestenosis fue tratada en 11 pacientes (18,6%). La Revascularizaci&#243;n quir&#250;rgica en tres (uno con reestenosis &gt; 50% y &lt; 70% y angina) y angioplastia en 8 (dos con reestenosis &gt; 50,0% y &lt;70,0% y angina). En 6 pacientes con reestenosis, no hubo ning&#250;n procedimiento. En 7 pacientes, se llev&#243; a cabo angioplastia en arterias no relacionadas al infarto. No hubo muertes durante el seguimiento.</p>
      <p>Cuarenta y cuatro pacientes evolucionaron asintom&#225;ticos durante el primer a&#241;o, 11 presentaron dolor en precordial hasta el 6&#186; mes (7 con reestenosis, de los cuales 5 con lesi&#243;n <underline>&gt;</underline> 70,0%) y 9 refirieron s&#237;ntomas despu&#233;s de 6 meses de evoluci&#243;n.</p>
      <p>
        <bold>Discusi&#243;n</bold>
      </p>
      <p>La reestenosis angiogr&#225;fica se produjo en 17 pacientes (28,8%). En los estudios PAMI-PILOTO<sup>18</sup>, STENT-PAMI<sup>16</sup> y CADILLAC<sup>3</sup>, y las tasas fueron un 27,0%, 23,0% y 22,0% respectivamente. Seg&#250;n lo descrito por Cutlip et al<sup>19</sup>, seguimos a los pacientes durante un a&#241;o para estimar el &#237;ndice real de &#233;xito<sup>19</sup>. En los estudios STENT-PAMI y CADILLAC, el seguimiento se realiz&#243; por 6 meses, y, en el GRAMI<sup>20</sup> y STENTIM<sup>21</sup>, se mantuvo durante un a&#241;o.</p>
      <p>La reintervenci&#243;n tard&#237;a despu&#233;s de ACPP se produce desde el 3,6% al 22,7% de los casos <sup>3, 16, 22</sup>. En el presente estudio, la revascularizaci&#243;n del vaso blanco fue de un 18,6%. La indicaci&#243;n apropiada de las pruebas no invasivas para la detecci&#243;n de reestenosis despu&#233;s de la ACPP sigue siendo a&#250;n controvertida. La PE se utiliza rutinariamente para detectar isquemia residual, la determinaci&#243;n de la capacidad funcional y la estratificaci&#243;n del riesgo despu&#233;s de un infarto agudo de miocardio, adem&#225;s de ser el examen m&#225;s frecuente realizado para evaluar los pacientes sometidos a intervenci&#243;n percut&#225;nea<sup>23-25</sup>.</p>
      <p>Se sabe que el ejercicio agudo puede inducir estado protromb&#243;tico transitorio en pacientes con enfermedad coronaria<sup>26</sup>. Casos de trombosis del stent, que tuvieron lugar horas despu&#233;s de la PE, fueron previamente descritos<sup>27,28</sup>. En nuestro estudio, las PE se llevaron a cabo sin complicaciones.</p>
      <p>Las directrices actuales para la realizaci&#243;n de hora despu&#233;s de la intervenci&#243;n percut&#225;nea no se recomienda realizar la prueba de rutina para detectar reestenosis<sup>11</sup>, pero no hay datos suficientes para determinar la estrategia correcta, especialmente en pacientes con alto riesgo de reestenosis como en las lesiones proximales de la EA.</p>
      <p>El racional de la estrategia de indicaci&#243;n rutinaria de pruebas funcionales tras ICP est&#225; fundamentado en la teor&#237;a de que el diagn&#243;stico de isquemia silenciosa les permite estratificar a los pacientes de peor pron&#243;stico<sup>5</sup>. Estudios previamente realizados demostraron que la PE presenta baja sensibilidad y limitada capacidad para ubicaci&#243;n de la isquemia<sup>11,29</sup>. El dolor precordial no representa &#237;ndice confiable de desarrollo de reestenosis despu&#233;s de intervenciones percut&#225;neas, una vez que aproximadamente el 50% de los pacientes con reestenosis permanecen asintom&#225;ticos y, inversamente, hasta el 45% de los pacientes que desarrollan dolor precordial no tienen reestenosis angiogr&#225;fica. Por esta raz&#243;n, no realizamos el estudio solo con pacientes asintom&#225;ticos.</p>
      <p>En los pacientes con revascularizaci&#243;n incompleta, la respuesta isqu&#233;mica puede ser consecuente a la reestenosis o la isquemia mioc&#225;rdica no est&#225; relacionada con el vaso tratado.</p>
      <p>Los datos de meta-an&#225;lisis refieren sensibilidad y especificidad de la PE en el 46% y el 77%, respectivamente, para lesi&#243;n resten&#243;tica &gt; 50% y 50% y 84% respectivamente para la reestenosis &gt; 70%<sup>29</sup>. La PE realizada 6 semanas tras el infarto evidenci&#243; baja sensibilidad y especificidad moderada. Aunque la PE para la identificaci&#243;n de reestenosis se realice en el 6&#186; mes, no encontramos sensibilidad y especificidad superiores a los obtenidos en el PE precoz, pero el elevado valor predictivo negativo resalta la importancia de la prueba no isqu&#233;mica en el abordaje cl&#237;nico de estos pacientes.</p>
      <p>Se refirieron resultados similares de sensibilidad y especificidad, con menor valor predictivo negativo (61%) en pacientes sintom&#225;ticos despu&#233;s de la intervenci&#243;n percut&#225;nea<sup>25</sup>. El primer estudio comparativo entre la estrategia rutinaria y selectiva para la realizaci&#243;n de la PE tras intervenciones percut&#225;neas fue el estudio ADORE, que evalu&#243; a pacientes sometidos a revascularizaci&#243;n completa sin reestudio angiogr&#225;fico durante la evoluci&#243;n. La realizaci&#243;n rutinaria de PE no mostr&#243; beneficios sobre la estrategia selectiva en que los pacientes que llevaron a cabo PE desencadenaron por s&#237;ntomas<sup>30</sup>.</p>
      <p>En este estudio, no hubo asociaci&#243;n con reestenosis ante la revascularizaci&#243;n completa o incompleta, incluso en los pacientes que ultrapasaron el 85% de la frecuencia cardiaca m&#225;xima prevista. Nuestros datos confirman la baja sensibilidad de la angina y los cambios electrocardiogr&#225;ficos provocados por el esfuerzo para detectar reestenosis<sup>31</sup>.</p>
      <p>No observamos una mejor sensibilidad de la PE con la adici&#243;n de las derivaciones precordiales derechas, similar a lo que se describi&#243; en otros estudios<sup>32,33</sup> y de modo contrario a los resultados obtenidos por Michaelides et al<sup>4</sup>.</p>
      <p>La media de METS alcanzada fue de 8, lo que puede explicarse por los rigurosos criterios de inclusi&#243;n como fracci&#243;n de eyecci&#243;n &gt; 40%. En pacientes tras infarto, la capacidad funcional &gt; 4 METS en asociaci&#243;n con una fracci&#243;n de eyecci&#243;n del ventr&#237;culo izquierdo <underline>&gt;</underline> 40,0% present&#243; correlaci&#243;n con una buena evoluci&#243;n<sup>34</sup>. De acuerdo con el estudio DANAMI-2, pacientes con baja capacidad funcional despu&#233;s de infarto agudo de miocardio presentan &#237;ndices de mortalidad m&#225;s altos<sup>35</sup>.</p>
      <p>La PE asociada a la GPM muestra un mejor desempe&#241;o diagn&#243;stico que la prueba de esfuerzo aislada<sup>25</sup>. La GPM es frecuentemente realizada tras intervenciones percut&#225;neas para detectar reestenosis e identificar otras &#225;reas de isquemia mioc&#225;rdica correspondientes a vasos no tratados<sup>36</sup>. En nuestro estudio, la GPM realizada en la 6&#170; semana se evidenci&#243; como baja sensibilidad que puede ser explicada por lesiones intermediarias o por uso de medicaciones. La especificidad y valor predictivo negativo mostraron valores moderados.</p>
      <p>Debido a las altas tasas de falsos positivos, la gammagraf&#237;a mioc&#225;rdica precoz, realizada durante los primeros tres meses tras intervenciones percut&#225;neas, no se debe indicar rutinariamente<sup>5</sup>. Rodes Cabau et al<sup>37</sup> observaron defectos reversibles en el 17% de los pacientes sometidos a la GPM una semana tras ACPP, con sensibilidad del 50% y especificidad del 54%. Sin embargo este hecho puede no excluir la posibilidad de reestenosis. En dos casos de nuestra muestra, en que los pacientes con s&#237;ndrome coronario agudo durante el cuarto mes de evoluci&#243;n, no se observ&#243; isquemia reversible seis semanas despu&#233;s de la ACPP.</p>
      <p>En nuestro estudio, la GPM realizada a los 6 y 12 meses mostr&#243; una baja sensibilidad, pero una alta especificidad, sobre todo en el 6 mes, teniendo en cuenta el <italic>summed difference score &gt;</italic> 2 y &gt; 4. Datos de sensibilidad, especificidad, valor predictivo positivo y valor predictivo negativo pueden haber sido influido por la terap&#233;utica vigente. La exactitud de la GPM llevada a cabo 6 meses despu&#233;s de la intervenci&#243;n suele ser muy buena<sup>5</sup>.</p>
      <p>Galassi et al <sup>31</sup> encontraron una precisi&#243;n similar (83,0%) en pacientes que alcanzaron o no la frecuencia card&#237;aca m&#225;xima durante la PE asociada a la GPM. Los autores concluyeron que lo m&#225;s importante es la homogeneidad de la poblaci&#243;n, un estudio similar a &#233;ste, en cuanto al tipo de estr&#233;s y al tiempo transcurrido entre el procedimiento percut&#225;neo y la gammagraf&#237;a y la gammagraf&#237;a y el reestudio angiogr&#225;fico. La inclusi&#243;n de los territorios con infarto previo no afect&#243; la precisi&#243;n de la GPM. A diferencia de nuestro estudio, los autores evaluaron s&#243;lo revascularizaciones completas.</p>
      <p>Isaaz et al<sup>38</sup> refirieron, en un estudio reciente, una baja correlaci&#243;n entre la gammagraf&#237;a con SPECT y reestenosis angiogr&#225;fica en el 6&#186; mes en 149 pacientes tratados por ACPP, que permanecieron asintom&#225;ticos durante el seguimiento. Para la detecci&#243;n de reestenosis, la sensibilidad, especificidad, valor predictivo positivo y valor predictivo negativo y precisi&#243;n fueron el 48%, el 61%, el 35%, el 72% y el 57%, respectivamente<sup>38</sup>. Por dos a&#241;os y medio, los autores siguieron a 78 pacientes, solamente a los uniarteriales.</p>
      <p>Nuestros resultados mostraron una mejor especificidad y un valor predictivo negativo. Kosa et al<sup>39</sup> informaron que las alteraciones preexistentes de la perfusi&#243;n mioc&#225;rdica en territorios con infarto previo puede dar lugar a una menor sensibilidad y especificidad. Poblaciones heterog&#233;neas pueden ser responsables de algunas discrepancias observadas en los estudios.</p>
      <p>La sensibilidad y la especificidad da com, observada en tiempos distintos tras las intervenciones percut&#225;neas, que var&#237;an desde el 39% al 100% y entre el 46% y el 100%, aumentando proporcionalmente al tiempo transcurrido tras la revascularizaci&#243;n<sup>5</sup>.</p>
      <p>La presencia de defectos reversibles a la GPM realizada entre 12 y 18 meses despu&#233;s de las intervenciones percut&#225;neas se asocia con un mayor riesgo de eventos durante la evoluci&#243;n. La extensi&#243;n y la severidad de los defectos reversibles de la perfusi&#243;n al SPECT tienen un alto valor predictivo para la sobrevida tard&#237;a despu&#233;s de intervenciones percut&#225;neas<sup>15</sup>. Este dato justific&#243; la realizaci&#243;n de la gammagraf&#237;a tras un a&#241;o del procedimiento en nuestro estudio.</p>
      <p>La fracci&#243;n de eyecci&#243;n determinada por el GATED-SPECT cuando &lt; 40,0% estaba relacionada con un mal pron&#243;stico en el seguimiento cl&#237;nico<sup>40</sup>. En nuestra casu&#237;stica, la buena evoluci&#243;n se puede explicar por la fracci&#243;n de eyecci&#243;n &gt; 45% observada en las gammagraf&#237;as evolutivas. Sabemos que los pacientes con fracci&#243;n de eyecci&#243;n&gt; 40,0% no representan la totalidad del mundo real, sino embargo, en centros terciarios, la ACPP puede realizar durante las primeras horas de evoluci&#243;n del IAM, as&#237; es posible encontrar a pacientes con fracci&#243;n de eyecci&#243;n preservada</p>
      <p>
        <bold>Implicaciones cl&#237;nicas</bold>
      </p>
      <p>El valor predictivo negativo de la GPM realizada 6 meses despu&#233;s de la ACPP es alta. La ausencia de isquemia reversible puede considerarse indicativa de la ausencia de reestenosis (o de la expresi&#243;n funcional de la reestenosis) en esta muestra seleccionada de pacientes.</p>
      <p>
        <bold>Limitaciones del estudio</bold>
      </p>
      <p>Citamos el peque&#241;o n&#250;mero de la muestra, la inclusi&#243;n de los pacientes que evolucionaron en clase Killip 1, fracci&#243;n de eyecci&#243;n <underline>&gt;</underline> 40,0 % y el mantenimiento de la medicaci&#243;n prescripta durante todo el protocolo. La muestra fue peque&#241;a debido a la coexistencia de m&#250;ltiples protocolos en marcha en ambas Instituciones, lo que no hac&#237;a posible la inclusi&#243;n de un mismo paciente en diferentes protocolos.</p>
      <p>La elecci&#243;n de los pacientes con fracci&#243;n de eyecci&#243;n &gt; 400% se hizo para asegurar la realizaci&#243;n de las pruebas ergom&#233;tricas. El mantenimiento de medicaciones como betabloqueantes puede afectar la respuesta de la frecuencia card&#237;aca al esfuerzo, pero nuestra intenci&#243;n fue evaluar la muestra del mundo real de los pacientes tras ACPP.</p>
      <p>
        <bold>Conclusiones</bold>
      </p>
      <p>Podemos llega a la conclusi&#243;n que la PE mostr&#243; una baja sensibilidad para la detecci&#243;n de reestenosis despu&#233;s de la ACPP durante el seguimiento cl&#237;nico. La adici&#243;n de derivaciones precordiales no proporcion&#243; informaciones adicionales. La GPM realizada 6 meses despu&#233;s del procedimiento present&#243; correlaci&#243;n con la reestenosis, evidenciando una alta especificidad y VPN en esta poblaci&#243;n de pacientes.</p>
      <p>
        <bold>Potencial Conflicto de Intereses</bold>
      </p>
      <p>Declaro no haber conflicto de intereses pertinentes.</p>
      <p>
        <bold>Fuentes de Financiaci&#243;n</bold>
      </p>
      <p>El presente estudio no tuvo fuentes de financiaci&#243;n externas.</p>
      <p>
        <bold>Vinculaci&#243;n Acad&#233;mica</bold>
      </p>
      <p>Este art&#237;culo forma parte de la tesis de Doctorado Rica Dodo Delmar Buchler por la Facultad de Medicina de la Universidad de S&#227;o Paulo.</p>
      <p>
        <bold>Referencias</bold>
      </p>
    </body>
  </sub-article>
  <sub-article article-type="translation" id="TRen" xml:lang="en">
    <front-stub>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title xml:lang="en">Noninvasive assessment of patients undergoing percutaneous intervention in myocardial infarction</article-title>
      </title-group>
      <abstract xml:lang="en">
        <p>BACKGROUND: Restenosis after primary percutaneous coronary intervention (PPCI) remains an important clinical problem, even with stent implantation. The ability of noninvasive testing to diagnose restenosis has had only inconsistent demonstration. OBJECTIVE: Our objective was to evaluate the ability of exercise treadmill testing (ETT) and myocardial perfusion imaging (MPI) to diagnose restenosis in patients treated by PPCI within 12 hours of ST-elevation myocardial infarction (STEMI). METHODS: From August 2003 to January 2006, 64 patients (mean age of 56.2&#177;10.2 years, 53 males) were enrolled after PPCI. Only patients with left ventricular ejection fraction (LVEF) &gt; 40%, as assessed by resting transthoracic echocardiography (TTE), were included. ETT with 12-lead ECG monitoring and right precordial leads, as also MPI were performed at 6 weeks, 6 months, and one year after intervention. Coronary angiography was performed at six months. RESULTS: Single-vessel disease was observed in 46.9% of the patients. The left anterior descending coronary artery was treated in 48.4% of the patients. Angiographic restenosis occurred in 28.8%. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of ETT in detecting restenosis were not significant. Right precordial leads did not add information. MPI sensitivity, specificity, PPV, NPV, and accuracy correlated with restenosis only in the 6-month follow-up, both when considering summed difference score &gt;2 (p=0.006) and &gt;4 (p=0.014). CONCLUSION: ETT did not discriminate restenosis in this population. MPI performed at 6 months correlated with restenosis and proved useful during follow-up.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <kwd>Coronary restenosis</kwd>
        <kwd>angioplasty</kwd>
        <kwd>stent</kwd>
        <kwd>myocardial infarction</kwd>
        <kwd>critical pathways</kwd>
      </kwd-group>
    </front-stub>
    <body>
      <p>
        <fn id="tx-body3">
          <label>
            <bold>Noninvasive assessment of patients undergoing percutaneous intervention in myocardial infarction</bold>
          </label>
          <p>
            <bold>Rica Dodo Delmar Buchler; Expedito E. Ribeiro; Antonio de Padua Mansur; Paola Smanio; Romeu Sergio Meneghelo; William Azem Chalela; Carlos Alberto Buchpiguel; Jorge Roberto Buchler; Eric R. Bates; Eulogio E. Martinez</bold>
          </p>
        </fn>
      </p>
      <p> Instituto do Cora&#231;&#227;o (InCor) da Faculdade de Medicina da Universidade de S&#227;o Paulo, Instituto Dante Pazzanese de Cardiologia, University Of Michigan - AnnArbor - Michigan</p>
      <p> Mailing address</p>
      <p>
        <bold>ABSTRACT</bold>
      </p>
      <p><bold>BACKGROUND:</bold> Restenosis after primary percutaneous coronary intervention (PPCI) remains an important clinical problem, even with stent implantation. The ability of noninvasive testing to diagnose restenosis has had only inconsistent demonstration.</p>
      <p><bold>OBJECTIVE:</bold> Our objective was to evaluate the ability of exercise treadmill testing (ETT) and myocardial perfusion imaging (MPI) to diagnose restenosis in patients treated by PPCI within 12 hours of ST-elevation myocardial infarction (STEMI).</p>
      <p><bold>METHODS:</bold> From August 2003 to January 2006, 64 patients (mean age of 56.2 &#177; 10.2 years, 53 males) were enrolled after PPCI. Only patients with left ventricular ejection fraction (LVEF) <underline>&gt;</underline> 40%, as assessed by resting transthoracic echocardiography (TTE), were included. ETT with 12-lead ECG monitoring and right precordial leads, as also MPI were performed at 6 weeks, 6 months, and one year after intervention. Coronary angiography was performed at six months.</p>
      <p><bold>RESULTS:</bold> Single-vessel disease was observed in 46.9% of the patients. The left anterior descending coronary artery was treated in 48.4% of the patients. Angiographic restenosis occurred in 28.8%. Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and accuracy of ETT in detecting restenosis were not significant. Right precordial leads did not add information. MPI sensitivity, specificity, PPV, NPV, and accuracy correlated with restenosis only in the 6-month follow-up, both when considering summed difference score &gt;2 (p=0.006) and &gt;4 (p=0.014).</p>
      <p><bold>CONCLUSION:</bold> ETT did not discriminate restenosis in this population. MPI performed at 6 months correlated with restenosis and proved useful during follow-up. </p>
      <p><bold>Key words:</bold> Coronary restenosis; angioplasty; stent; myocardial infarction; critical pathways.</p>
      <p>
        <bold>Introduction</bold>
      </p>
      <p>Primary percutaneous coronary intervention (PPCI) is superior to fibrinolytic therapy in the treatment of ST-elevation myocardial infarction (STEMI)<sup>1</sup>. Due to high rates of restenosis, coronary stenting has emerged as a new strategy, but restenosis still remains a major limitation, with rates for bare-metal stenting ranging from 20% to 25%<sup>2,3</sup>.</p>
      <p>Appropriate use of noninvasive testing following PPCI has not been systematically investigated. Among the noninvasive tests, exercise treadmill test (ETT) and myocardial perfusion imaging (MPI) have been used to detect restenosis. ETT is safe, simple, and easy to perform. Adding right precordial leads has been used to improve ETT sensitivity<sup>4</sup>. In contrast, the sensitivity and specificity of MPI in detecting restenosis after PCI range from 39% to 100 % and 46% to 100%, respectively, and improve with time after revascularization<sup>5</sup>.</p>
      <p>The purpose of the present study was to determine the prognostic value of ETT and MPI in the detection of in-stent restenosis during PPCI follow-up.</p>
      <p>
        <bold>Patients and Methods</bold>
      </p>
      <p>Primary balloon angioplasty and stenting during the acute phase of myocardial infarction was performed in two centers by experienced surgeons. </p>
      <p>The patients underwent ETT, and MPI at 6 weeks, 6 months, and 1 year after intervention. </p>
      <p>ETTs were performed with the patients using the medication prescribed, including betablockers. Follow-up coronary angiography was performed at six months. Resting TTE was performed prior to hospital discharge, to evaluate left ventricular ejection fraction (LVEF) and to include the patient in the protocol. </p>
      <p>The study was approved by both institutional ethics committees and all patients gave written informed consent. The study was conducted in accordance with the clinical principles of the Declaration of Helsinki regarding research in humans.</p>
      <p>
        <bold>Patients</bold>
      </p>
      <p>From August 2003 to January 2006, 80 patients treated with PPCI and stenting within 12 hours of STEMI were prospectively selected at <italic>Instituto do Cora&#231;&#227;o</italic> (InCor) and at <italic>Instituto Dante Pazzanesede Cardiologia</italic> in S&#227;o Paulo, Brazil. </p>
      <p>The inclusion criteria were: age <underline>&lt;</underline>75 years, no prior myocardial infarction, Killip class 1<sup>6</sup>, resting LVEF <underline>&gt;</underline> 40% by TTE, and ability to perform ETT. Bare metal stents were used in all patients. Sixteen patients (20%) were excluded: 5 did not meet the echocardiographic inclusion criteria and 11 withdrew before the final assessment. The remaining 64 patients were followed up for at least one year.</p>
      <p>All interventions were performed according to current guidelines, including periprocedural glycoprotein IIb/IIIa inhibitors at the surgeon's discretion<sup>7</sup>. </p>
      <p>Angiographic success was defined as residual stenosis in the target vessel <underline>&lt;</underline> 30% and presence of TIMI flow grade 3<sup>8</sup>. Only the infarct artery was treated.</p>
      <p>
        <bold>Study protocol</bold>
      </p>
      <p>
        <bold>TTE</bold>
      </p>
      <p> TTE studies were performed before hospital discharge with a 3-MHz Ultramark-9 HDI equipment (Advanced Technology Laboratories Inc., Cherry Hills, NJ). The methodology was focused on LVEF determined by Simpson's method<sup>9</sup>. TTE defined the inclusion and further maintenance of the patients inclusion in this protocol.</p>
      <p>
        <bold>ETT</bold>
      </p>
      <p> All patients underwent symptom-limited ETT using the Bruce protocol<sup>10</sup> and gated-SPECT myocardial perfusion imaging. The patients were monitored by a 12-lead ECG and right precordial leads V3R, V4R, and V5R in order to increase sensitivity and specificity. ETT was performed according to standard guidelines<sup>11</sup>. </p>
      <p>Functional capacity was assessed by exercise duration in minutes and number of METS achieved, applying the Bruce equation<sup>12</sup>(1 MET= 3.5 ml/O<sub>2</sub>/kg/min). </p>
      <p>Electrocardiographic criteria for ischemia were present if <underline>&gt;</underline>1 mm horizontal or upslopping ST-segment depression 80 miliseconds after the J point occurred in more than three consecutive QRS complexes with or without chest pain. Downslopping depression was measured at J point. </p>
      <p>Typical angina was a clinical criterion for myocardial ischemia. The Duke treadmill score was calculated as previously described<sup>13</sup>. </p>
      <p>At peak exercise, 444 to 555 mBQ of Technetium-99m sestamibi were administered intravenously in bolus. The patients continued to exercise for one additional minute before exercise termination. Before the exercise, sestamibi was injected at rest in the same dose. Gated-SPECT scyntigraphy was performed between 60 and 90 minutes after tracer injection.</p>
      <p>
        <bold>Myocardial-SPECT perfusion image acquisition protocol</bold>
      </p>
      <p>All acquisitions were performed as described elsewhere<sup>14</sup>. SPECT (Single Photon Emission Computed Tomography) was performed in a rotating gamma camera (CardioMD, Philips Medical Systems, Milpitas, CA, USA). </p>
      <p>Images were acquired using a 64 x 64 image matrix, and a 20% window centered in 140 keV peak. Qualitative and semiquantitative analyses were used to study myocardial perfusion. </p>
      <p>For the quantitative analysis, perfusion was classified as normal; transient ischemia (low uptake during exercise only); fibrosis or fixed hypoperfusion (low uptake in both phases); and both fixed and transient hypoperfusion (coexistence of ischemic and fibrotic tissue, low uptake during the stress phase with partial improvement during the resting phase). Two independent observers analyzed the scintigraphic studies. </p>
      <p>For the semiquantitative analysis, the left ventricle was divided into 17 anatomic segments and the perfusion defects were analyzed using a score system ranging from zero to 4: 0- normal tracer uptake, 1- mild reduction, 2- moderate reduction, 3- severe reduction, and 4- absence of tracer uptake. </p>
      <p>Summed stress scores were obtained by adding the scores of the 17 segments of the stress images, and summed rest scores by adding the scores of the 17 segments at rest. </p>
      <p>The summed difference score representing the amount of ischemic myocardium was defined as the difference between the stress and rest scores<sup>15</sup>. A summed difference score &gt;2 was considered a reversible defect. </p>
      <p>The analysis of all segments allowed us to identify ischemia related to other coronary lesions not treated by PPCI.</p>
      <p>
        <bold>Follow-up coronary angiography</bold>
      </p>
      <p>All angiographic procedures were performed according to the Judkins technique 6 months after PPCI, using 5 to 6 French guiding catheters. </p>
      <p>In-stent restenosis was defined as a <underline>&gt;</underline>50% diameter stenosis on quantitative coronary angiography.</p>
      <p>
        <bold>Endpoints</bold>
      </p>
      <p>Major cardiac events were defined as death, nonfatal myocardial infarction, or target vessel revascularization. </p>
      <p>Myocardial infarction was defined according to criteria described elsewhere<sup>16</sup>. </p>
      <p>Target vessel revascularization was defined as a repeat intervention (either surgical or percutaneous) resulting from any lesion located in the vessel treated.</p>
      <p>
        <bold>Statistical analysis</bold>
      </p>
      <p>Continuous variables were expressed as mean and standard deviation and were compared using the Student's <italic>t </italic>test. </p>
      <p>Categorical variables were described as absolute and relative frequencies. </p>
      <p>Sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were calculated for ETT and MPI considering follow-up coronary angiography results. </p>
      <p>Associations between categorical variables were verifed using the chi square test or the Fischer's exact test. </p>
      <p>The Student's <italic>t</italic> test or the nonparametric Mann-Whitney test were used for non-normally distributed continuous variables.</p>
      <p>The significance level was set at 0.05. Interobserver agreement for the interpretation of the myocardial perfusion images was evaluated using the Kappa statistics.</p>
      <p>
        <bold>Results</bold>
      </p>
      <p>The clinical characteristics of the patients are shown in <xref ref-type="table" rid="tab1-body3">Table 1</xref>. </p>
      <table-wrap id="tab1-body3">
        <graphic xlink:href="1678-4170-abc-95-05-0555-00139-gt01-en.jpg"/></table-wrap>
      <p>The mean time from the onset of symptoms to treatment was 4 hours and the mean door-to-balloon time was 75 minutes.</p>
      <p>
        <bold>Coronary angiography</bold>
      </p>
      <p>The left anterior descending artery was treated in 31 patients (48.4%), the right coronary artery in 22 (34.4%), the left circumflex in 7 (10.9%), the left main coronary artery in 2 (3.1%), the large diagonal branch in 1 (1.56%), and a saphenous vein bypass graft in 1 (1.56%). </p>
      <p>Multivessel disease (other coronary lesions <underline>&gt;</underline> 50%) was found in 34 patients (53.1%). </p>
      <p>Complete revascularization was achieved in 30 patients with single vessel disease and in three with multivessel disease previously revascularized. </p>
      <p>Mean pre- and post- procedural reference diameters were 2.9 &#177; 0.5 mm and 3.2 &#177; 0.4 mm, respectively. Mean pre- and post- procedural minimal luminal diameters were 0.34 &#177; 0.4 mm and 2.81&#177; 0.4 mm, and mean pre- and post-procedural diameter stenoses were 87.7% &#177; 14.6 % and 7.5 &#177; 4.2%. respectively.</p>
      <p>Follow-up coronary angiography was performed in 59/64 patients, 3 before six months (one in the third month due to angina and 2 in the fourth month due to acute coronary syndrome). </p>
      <p>Angiographic restenosis occurred in 17 patients (28.8%), 8 with 50.0%-70.0% stenosis and 9 with <underline>&gt;</underline> 70% stenosis. Repeat target vessel revascularization was performed in 18.6% of the cases. The final reference vessel diameter was 2.63 &#177; 0.72 mm and final minimal luminal diameter was 1.95 &#177; 0.90 mm. Final mean percent diameter stenosis was 39 &#177; 25.0%. </p>
      <p>No difference in restenosis occurred in patients with single or multivessel disease.</p>
      <p>
        <bold>TTE</bold>
      </p>
      <p>The mean LVEF found in the tests for patient inclusion in the protocol was 0.55.</p>
      <p>
        <bold>ETT</bold>
      </p>
      <p>The tests were performed with the patients receiving the medication prescribed after hospital discharge.</p>
      <p>During the ETT performed at 6 weeks, 6 months, and 12 months, 85.0%, 79.0%, and 66.7% of the patients were using betablockers, and 45.9%, 7.5%, and 7.5% were using clopidogrel or ticlopidine, respectively. ETT data are shown in <xref ref-type="table" rid="tab2-body3">Table 2</xref>.</p>
      <table-wrap id="tab2-body3">
        <graphic xlink:href="1678-4170-abc-95-05-0555-00139-gt02-en.jpg"/></table-wrap>
      <p>Sensitivity, specificity, PPV, NPV, and accuracy regarding results of ETT compared with follow-up angiography are seen in <xref ref-type="table" rid="tab3-body3">Table 3</xref>. When considering patients who reached 85.0% of maximum predicted heart rate, sensitivity, specificity, PPV, NPV, and accuracy for the detection of restenosis were 63.6%, 67.7%, 41.2%, 84.0%, and 66,7%, respectively, at 6 weeks (p=0.086); 55.6%, 83.3%, 55.6%, 83.3%, and 75.7% at 6 months (p=0.073); and 40.0%, 66.7%, 30.8%, 75.0%, and 59.4% at 12 months (p= 0.716) after treatment of myocardial infarction.</p>
      <table-wrap id="tab3-body3">
        <graphic xlink:href="1678-4170-abc-95-05-0555-00139-gt03-en.jpg"/></table-wrap>
      <p>There was no correlation between restenosis and the Duke treadmill score, exercise duration, exercise angina, ST-segment depression, or right precordial lead abnormalities. </p>
      <p>An increase in exercise duration was observed between the first and the second ETT (p=0.004) and between the first and the third ETT (p=0.004) in the 46 patients who performed all 3 tests. The same was observed for the number of METS achieved (p=0.002 and p=0.004, respectively).</p>
      <p>
        <bold>Myocardial perfusion imaging</bold>
      </p>
      <p>The results of MPI according to qualitative analysis are summarized in <xref ref-type="table" rid="tab4-body3">Table 4</xref>. </p>
      <table-wrap id="tab4-body3">
        <graphic xlink:href="1678-4170-abc-95-05-0555-00139-gt04-en.jpg"/></table-wrap>
      <p>The semiquantitative analysis considered transient ischemia as a summed difference score &gt; 2; for the same sample scores &gt; 4 were also evaluated. </p>
      <p>The results of this analysis are shown in <xref ref-type="table" rid="tab5-body3">Table 5</xref>. Interobserver reproducibility showed substantial agreement with Kappa of 0.762 (95% CI 0.51-1.0), p &lt; 0.001<sup>17</sup>.</p>
      <table-wrap id="tab5-body3">
        <graphic xlink:href="1678-4170-abc-95-05-0555-00139-gt05-en.jpg"/></table-wrap>
      <p>The summed difference score during the first year in 46 patients who underwent all sequential MPI did not show any statistical significance (p=0.194). The comparison between summed difference scores performed 6 weeks, 6 months, and one year after PPCI and restenosis was not statistically significant (p = 0.056). </p>
      <p>Summed stress scores and summed rest scores were compared with restenosis in all MPI, and classified as 0 to 4, 4 to 8, and &gt;8 according to the amount of damaged myocardium. </p>
      <p>There was a correlation between the amount of damaged myocardium and restenosis at 1 year at rest (p=0.0019) and after exercise (p=0.004).</p>
      <p>
        <bold>Follow-up</bold>
      </p>
      <p>Angiographicrestenosis occurred in 17/59 patients (28.8%). Subacute stent thrombosis was observed 27 days after PPCI in 1 patient. Non-ST-elevation acute coronary syndrome occurred in 2 patients during the fourth month (one of them treated by surgical revascularization and the other by balloon angioplasty). </p>
      <p>Restenosis was treated in 11 patients (18.6%) by means of surgical revascularization in 3 (1 with restenosis &gt; 50.0% and &lt; 70.0% plus angina) and angioplasty in 8 (2 with restenosis &gt;50.0% and &lt; 70.0% plus angina). In 6 patients with restenosis, no procedure was performed. </p>
      <p>Angioplasty was performed in 7 patients in non-infarct arteries. No death was observed during follow-up. </p>
      <p>Forty-four patients remained asymptomatic during the first year, 11 patients had chest pain up to six months (7 with restenosis, of whom 5 had a lesion <underline>&gt;</underline>70.0% ), and 9 reported symptoms after 6 months of follow-up.</p>
      <p>
        <bold>Discussion</bold>
      </p>
      <p>Angiographic restenosis occurred in 17 patients (28.8%). Restenosis rates in the PAMI-PILOT study<sup>18</sup>, STENT-PAMI trial<sup>16</sup>, and CADILLAC study<sup>3</sup> were 27.0%, 23.0% and 22.0%, respectively. </p>
      <p>Similar to Cutlip et al<sup>19</sup>, we followed up our patients for one year to measure the real success rate<sup>19</sup>. </p>
      <p>The STENT-PAMI<sup>16</sup> and CADILLAC<sup>3</sup> trials followed up their patients for 6 months, while the GRAMI<sup>20</sup> and STENTIM<sup>21</sup> trials reported a 12-month follow-up. Late repeat intervention after PPCI was performed in 3.6% to 22.7% of the cases<sup>3,16,22</sup>. In our study, the rate of target vessel revascularization was 18.6%.</p>
      <p>The appropriate use of noninvasive tests for the diagnosis of restenosis after PPCI remains controversial. </p>
      <p>ETT is routinely used to detect residual ischemia, to assess exercise capacity, and for risk stratification after acute myocardial infarction. It is the most commonly used test for evaluating patients after PCI<sup>23-25</sup>.</p>
      <p>It is known that acute exercise can lead to a transient prothrombotic state in patients with coronary artery disease<sup>26</sup>. Cases of in-stent thrombosis within hours after ETT have been previously reported<sup>27,28</sup>. In our study, ETT was safely performed.</p>
      <p>The current ACC/AHA guidelines<sup>11</sup> for ETT post-PCI do not recommend routine screening for detection of restenosis, but there are insufficient data to determine the correct ETT strategy, especially in patients at high risk of restenosis such as those in the proximal LAD. </p>
      <p>The rationale of the strategy of routine indication of functional tests after PCI is based on the theory that the diagnosis of silent ischemia can stratify patients at higher risk<sup>5</sup>. Previous studies demonstrated that ETT has low sensitivity and ability to localize ischemia<sup>11,29</sup>. Chest pain is an unreliable index of restenosis after PCI, since approximately 50.0% of patients with restenosis remain asymptomatic and, conversely, up to 45.0% of patients developing chest pain do not have angiographic restenosis<sup>5</sup>.In patients with incomplete revascularization, the ischemic response may result from either stent restenosis or myocardial ischemia unrelated to the target vessel.</p>
      <p>A meta-analysis showed ETT sensitivity and specificity to be of 46.0% and 77.0%, respectively, for restenosis &gt; 50.0%; and 50.0% and 84.0%, respectively, for restenosis &gt; 70.0%<sup>29</sup>. ETT performed 6 weeks after myocardial infarction showed low sensitivity and moderate specificity. Although ETT for the detection of restenosis had been performed 6 months after the procedure, we did not find improved sensitivity and specificity in relation to the earlier ETT; however, its high negative predictive value stresses the importance of a nonischemic test in the clinical approach to these patients. </p>
      <p>Similar results regarding sensitivity and specificity, with lower negative predictive value (61.0%), were reported in symptomatic patients after PCI<sup>25</sup>. </p>
      <p>ADORE was the first trial to compare the strategies of routine and selective ETT after PCI; this study evaluated patients undergoing complete revascularization with no angiographic follow-up, and found no benefits with routine ETT in relation to selective ETT, which was performed in symptomatic patients<sup>30</sup>. </p>
      <p>In our study, no association with restenosis was found in the presence of complete or incomplete revascularization, even in patients who achieved more than 85.0% of maximum predicted heart rate. Our data confirm the low sensitivity of angina and electrocardiographic changes during exercise for the detection of restenosis<sup>31</sup>.</p>
      <p>Improved ETT sensitivity was not observed when right precordial leads were included; this corroborates the findings from other studies<sup>32,33</sup> but not Michaelides et al's findings<sup>4</sup>. </p>
      <p>The mean METS obtained was 8, which can be explained by our strict inclusion criteria, such as LVEF &gt; 40.0%. In post-infarction patients, exercise capacity &gt; 4 METS in association with LVEF <underline>&gt;</underline> 40.0% was correlated with a favorable outcome<sup>34</sup>. According to the DANAMI-2 trial, post-infarction patients with low exercise capacity had higher mortality rates<sup>35</sup>. </p>
      <p>Exercise MPI has better diagnostic ability than ETT alone<sup>25</sup>. MPI is frequently performed after PCI to detect restenosis and to identify other areas of myocardial ischemia unrelated to the target-vessel<sup>36</sup>. In our study, MPI performed at 6 weeks showed low sensitivity, which could be explained by intermediary lesions or by the use of medications. Specificity and negative predictive value were moderate. </p>
      <p>Given the high false positive rate, MPI early (&lt;3 months) after PCI should not be routinely indicated<sup>5</sup>. Rodes-Cabau et al<sup>37</sup> detected reversible defects in 17.0% of the patients who underwent MPI one week after PPCI, with 50.0% sensitivity and 54.0% specificity. Nevertheless, this finding may not exclude the possibility of restenosis. In 2 of our patients who presented with acute coronary syndrome during the fourth month of follow-up, no reversible ischemia was observed 6 weeks after PPCI.</p>
      <p>In our study, MPI performed at 6 and 12 months showed low rates of sensitivity, but high rates of specificity, especially at 6 months, considering summed difference score &gt; 2 and &gt; 4. Sensitivity, specificity, and positive and negative predictive values may have been affected by drug therapy. The accuracy of MPI performed 6 months following PCI is usually very good<sup>5</sup>.</p>
      <p>Galassi et al<sup>31</sup> found similar accuracy (83.0%) in patients who did or did not achieve maximum heart rate during exercise testing. The authors concluded that the most important characteristic is the homogeneity of the study population, like in our sample, in terms of type of stress and time interval between stenting and scintigraphy, and between scintigraphy and follow-up angiography. The inclusion of territories with previous myocardial infarction did not affect the accuracy of MPI. Unlike in our study, only complete revascularization was assessed. </p>
      <p>Isaaz et al<sup>38</sup> recently reported a poor correlation between stress SPECT imaging and angiographic restenosis at 6 months in 149 patients treated by PPCI who remained asymptomatic during the follow-up. They showed sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 48.0%, 61.0%, 35.0%, 72.0% and 57.0%, respectively, for the detection of restenosis. The authors followed up 78 patients with single vessel disease for two years and a half<sup>38</sup>. </p>
      <p>Our results showed better specificity and negative predictive value. Kosa et al<sup>39</sup> reported that preexisting myocardial perfusion abnormalities in territories with previous infarction may result in lower sensitivity and specificity values. Population heterogeneity may account for some of the discrepancies observed in these studies.</p>
      <p>The sensitivity and specificity of MPI performed at different times after PCI range from 39.0% to 100.0%, and from 46.0% to 100.0%, and improve with time after revascularization<sup>5</sup>.</p>
      <p>The presence of reversible defects on MPI performed between 12 and 18 months after PCI is associated with an increased risk of events in the follow-up. The extent and severity of reversible perfusion defects on SPECT strongly predict event-free survival late after PCI<sup>15</sup>. This information was the basis for including MPI assessment one year after the procedure in our study. </p>
      <p>LVEF &lt; 40.0% as determined by gated SPECT was correlated with a poor prognosis during follow-up<sup>40</sup>. In our case series, the good outcome may be explained by the LVEF &gt; 45.0% observed on follow-up MPI.We know that patients with ejection fraction &gt; 40.0% are not always found in the real world. However, in tertiary care centers, PPCI can be performed within the first few hours after myocardial infarction. Thus, it is possible to find patients with preserved ejection fraction and thereby obtain information from noninvasive tests similar to that obtained after elective PCI.</p>
      <p>
        <bold>Clinical implications</bold>
      </p>
      <p>The negative predictive value for MPI performed 6 months after the PPCI is high. The absence of reversible ischemia can be considered indicative of the absence of restenosis (or of the functional expression of restenosis) in these selected patient sample.</p>
      <p>
        <bold>Study limitations</bold>
      </p>
      <p>The limitations of this study include small sample size, inclusion of only Killip class 1 patients with LVEF <underline>&gt;</underline> 40.0%, and maintainence of usual medications during the entire protocol.</p>
      <p>The small sample was related to the occurrence of several trials running at the same time in both institutions, thus not allowing the same patient in more than one trial.</p>
      <p> The selection of patients with LVEF &gt; 40.0% was made to ensure that they could undergo ETT. </p>
      <p>Maintainance of drugs such as betablockers may affect the heart rate response to exercise, but our intention was to evaluate a real-world sample of patients after PPCI. </p>
      <p>
        <bold>Conclusions</bold>
      </p>
      <p>In conclusion, ETT showed low sensitivity to detect restenosis after PPCI during the follow-up. The inclusion of right precordial leads did not provide additional information. </p>
      <p>MPI performed 6 months after PPCI correlated with restenosis, showing high specificity and NPV in this patient population. </p>
      <p>
        <bold>Potential Conflict of Interest</bold>
      </p>
      <p> No potential conflict of interest relevant to this article was reported.</p>
      <p>
        <bold>Sources of Funding</bold>
      </p>
      <p> There were no external funding sources for this study.</p>
      <p>
        <bold>Study Association</bold>
      </p>
      <p> This article is part of the thesis of doctoral submitted by Rica Dodo Delmar Buchler, from <italic>Faculdade de Medicina da Universidade de S&#227;o Paulo</italic>.</p>
      <p>
        <bold>References</bold>
      </p>
    </body>
  </sub-article>
</article>
